Method for producing cyclized peptide having intramolecular SS bond
By forming a temporary S-S bond on the peptide and folding under redox conditions, the problems of reduced yield and low production efficiency caused by protective group residues and impurities in the production of cyclized peptides are solved, and an efficient cyclization reaction is achieved.
Patent Information
- Application Number
- CN201980074871.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-11-16
- Filing Date
- 2019-11-15
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-11-15
AI Technical Summary
In the prior art, when manufacturing cyclized peptides with S-S crosslinked structures, there is a problem of low yield due to protection group residues and impurities, and the need to perform cyclization reactions under low concentration conditions, which makes production efficiency low.
A new methodology is adopted to protect the SH group by forming temporary S-S bonds on the peptide and perform folding process under redox conditions to form a cyclized peptide, which includes deprotection of the fully protected peptide and the formation of temporary S-S bonds. , and then cyclization reaction is carried out under high concentration conditions.
It effectively overcomes the problem of yield reduction caused by protective group residues and impurities, and achieves efficient cyclization reaction under high concentration conditions, improving production efficiency.
Smart Images

Figure GDA0003286906830000121 
Figure GDA0003286906830000122 
Figure GDA0003286906830000161
Abstract
Description
Technical Field
[0001] The present invention relates to a method for producing a cyclized peptide having a cross-linked structure based on an intramolecular SS bond (disulfide bond), and is useful in the field of peptide synthesis. Background Art
[0002] It has been known that many peptides containing SS bonds are peptide drugs, such as somatostatin, octreotide, atosiban, etc. In recent years, research and development of cyclized peptides containing more than four SH groups in the molecule and having cyclized sites based on multiple SS cross-linked structures by forming SS bonds in the molecule through these SH groups (for example, linaclotide, plecanatide, ziconotide, insulindetemir, insulinglulisine, etc.) are underway.
[0003] In the past, in the synthesis of peptides that are cyclized by forming SS bonds within a molecule, after producing a linear peptide corresponding to the amino acid sequence of the target cyclized peptide, all the protecting groups of the functional groups constituting the amino acid residues, including the protecting group of the SH group, are deprotected to obtain an unprotected linear peptide, and the peptide thus obtained is subjected to oxidative conditions to form SS bonds, thereby synthesizing a cyclized peptide having a target cross-linked structure (see, for example, Patent Document 1). In Patent Document 1, an acid such as trifluoroacetic acid (TFA) is used to deprotect all the protecting groups possessed by the peptide, so that the SH group in the peptide also becomes unprotected, and therefore, there is a problem that the residues of various protecting groups after the SH group is deprotected are alkylated, the yield is reduced, and the impurities thereof cause a reduction in the yield of the target peptide in the subsequent cyclization reaction. Regarding the decrease in the yield of the target peptide in the cyclization reaction caused by by-product impurities, Patent Document 2 describes a method for producing a peptide, wherein a phenylacetylaminomethyl group (Phacm group, phenylacetamidemethyl) is used as a protecting group for the SH group of a cysteine residue, and the protecting groups of the functional groups of amino acid residues other than the cysteine residue of a linear peptide are deprotected while the SH group is protected, and then the Phacm protecting group is deprotected and an SS bond is formed under solid phase conditions.
[0004] In the manufacture of cyclized peptides containing more than 4 SH groups, there are more than 2 combinations of SS bond formation, so it is necessary to selectively form SS bonds between the target SH groups in the manufacturing process. In addition, regarding the reduction in the yield of the cyclization reaction, there are also the following issues: impurities after the SH groups in the peptide are alkylated, and sometimes the number of SH groups in the molecule is an odd number. In this case, multiple SS bonds as the target cannot be formed, and unprotected SH groups remain in the peptide, and side reaction products are generated between molecules, or the SH group itself acts as a reducing agent, and a side reaction that breaks the formed SS bonds occurs, so that the cyclization yield is reduced. In this regard, Patent Document 3 describes a method for manufacturing a peptide under solid phase conditions, wherein a linear peptide is designed in which the SH groups are protected in advance by other types of protecting groups (acetylaminomethyl (Acm group) and 4-methylbenzyl) according to the combination of SH groups in the peptide in which the SS bonds are desired to be formed, and then the deprotection process and oxidation process of the SH group protecting group are repeatedly performed in sequence according to the type of the protecting group, so as to form SS bonds between the SH groups in the target peptide.
[0005] In addition to the above, the conventional methods also have the following problems: the cyclization reaction based on the formation of intramolecular SS bonds usually needs to be carried out under low concentration conditions (under conditions using excess solvent) to suppress the side reaction of forming SS bonds between molecules, and the production efficiency is very low. Therefore, a highly efficient production method is needed that can effectively carry out the target cyclization reaction even if the substrate concentration during the cyclization reaction is increased.
[0006] Prior art literature
[0007] Patent Literature
[0008] Patent Document 1: International Publication No. 2014 / 188011
[0009] Patent Document 2: International Publication No. 2017 / 134687
[0010] Patent document 3: U.S. Patent No. 7,304,036. Summary of the invention
[0011] Technical problem to be solved by the invention
[0012] In the technical field, research has been conducted to solve the problem of producing cyclized peptides having SS cross-linked structures, but all of them are based on the formation of SS bonds by selecting protective groups for SH groups in peptides. Therefore, it is desired to develop a new method for producing cyclized peptides that is simpler and more effective. The present invention was created in response to such a problem.
[0013] Technical solutions adopted to solve technical problems
[0014] The present inventors have discovered a method for producing a cyclized peptide, which generally includes a step of efficiently obtaining a target cyclized peptide based on a new methodology, thereby completing the present invention; the new methodology is: using a peptide having two or more SH groups as functional groups on the peptide, using various preparation methods to temporarily form SS bonds between all SH groups and within the molecule, and other functional groups on the peptide are unprotected, and subjecting the peptide to a folding step under redox conditions to reform the SS bonds within the peptide molecule. Specifically, the present invention is a method for producing a cyclized peptide including the following steps.
[0015] [1] A method for producing a cyclized peptide, comprising:
[0016] (1-A) in a linear peptide having two or more SH groups as functional groups on the peptide, in which all SH groups are protected, the N-terminal amino group may be protected, and the C-terminal carboxyl group and other functional groups on the peptide are all protected (hereinafter sometimes referred to as "fully protected peptide"), a step of deprotecting the protecting groups of all functional groups of the peptide except the protected SH groups;
[0017] (1-B) a step of protecting all SH groups in a linear peptide having two or more SH groups as functional groups on the peptide by forming temporary SS bonds;
[0018] as well as
[0019] (2) A step in which a peptide having two or more SH groups as functional groups on the peptide obtained by the above steps (1-A) and (1-B), all of which are protected by forming temporary SS bonds, and all protecting groups of other functional groups on the peptide are deprotected (hereinafter sometimes referred to as "S-protected peptide" in this specification) is subjected to a folding step under redox conditions, and a cyclized peptide is obtained by re-forming SS bonds in the peptide molecule.
[0020] Protection of the SH group in the fully protected peptide in step (1-A) includes two forms: protection by a protective group for the SH group as described below and protection by forming a temporary SS bond.
[0021] In the present invention, the S-protected peptide of step (2) can be obtained by carrying out step (1-A) and step (1-B), but the order of carrying out step (1-A) and step (1-B) is not limited to this order, and the order can be appropriately changed according to the embodiment. Therefore, it may be a case where step (1-B) is carried out after step (1-A), a case where step (1-A) is carried out after step (1-B), a case where a combination of these is carried out, and a case where both steps are carried out simultaneously, all of which are included in the scope of the present invention (hereinafter, step (1-A) and step (1-B) are sometimes collectively referred to as step (1)).
[0022] [2] The method for producing a cyclized peptide according to [1], wherein:
[0023] In step (1-B), the protection of all SH groups by forming temporary SS bonds is achieved by "all SH groups forming temporary SS bonds within the peptide molecule and / or between peptide molecules" (hereinafter sometimes referred to as "temporary SSization" in this specification), or
[0024] In step (1-B), the protection of all SH groups by forming a temporary SS bond is achieved by forming a temporary SS bond with an S-type protecting group.
[0025] [3] The method for producing a cyclized peptide according to [1] or [2], wherein the S-protected peptide is obtained by any of the following steps:
[0026] (1) In step (1-B), the fully protected peptide is subjected to temporary SS-reaction to obtain a mixture of peptides cross-linked or linked by temporary SS bonds (hereinafter sometimes referred to as "temporary SS-reaction peptide mixture" in this specification), and then,
[0027] In step (1-A), a step of obtaining an S-protected peptide by deprotecting the protecting groups of all functional groups of the temporarily SS-formed peptide mixture except the SH group protected by forming a temporary SS bond;
[0028] (2) In step (1-A), the protecting groups of all functional groups other than the SH group of the fully protected peptide are deprotected, and subsequently or simultaneously, in step (1-B), the deprotected peptide is subjected to temporary SS-reaction to obtain a temporary SS-reaction peptide mixture, thereby obtaining an S-protected peptide;
[0029] (3) a) In step (1-A), all protective groups of the fully protected peptide except the SH group are deprotected, and then,
[0030] 2) Remove the SH protecting group, and then
[0031] 3) In step (1-B), the peptide mixture is temporarily SS-treated to obtain a temporarily SS-treated peptide mixture, or
[0032] b) 1) removing the protecting groups of the SH groups of the fully protected peptide, and then,
[0033] 2) In step (1-B), the peptide mixture is temporarily SS-treated to obtain a temporarily SS-treated peptide mixture, and then
[0034] 3) In step (1-A), a step of obtaining an S-protected peptide by deprotecting the protecting groups of all functional groups of the temporarily SS-treated peptide mixture except the SH group protected by forming a temporary SS bond;
[0035] or
[0036] (4) in step (1-B), the protective groups of the SH groups of a linear peptide having two or more SH groups protected by protective groups as functional groups on the peptide, wherein the N-terminal amino group may be protected and the C-terminal carboxyl group and all other functional groups on the peptide are protected, are re-protected with an S-type protective group, or the peptide is pre-protected with an S-type protective group, thereby obtaining a peptide in which all SH groups are protected by forming temporary SS bonds with S-type protective groups;
[0037] In step (1-A), the protecting groups of all functional groups of the peptide except the SH group temporarily protected by SS bond are deprotected to obtain an S-protected peptide.
[0038] [4] The method for producing a cyclized peptide according to any one of [1] to [3], wherein in step (1-B), protection of all SH groups by forming temporary SS bonds is accomplished by temporary SS-reduction;
[0039] [5] The method for producing a cyclized peptide according to [4], wherein the temporary SS-replacement is performed by iodine treatment or thallium (III) trifluoroacetate treatment;
[0040] [6] The method for producing a cyclized peptide according to [5], wherein the temporary SS-reaction is performed by iodine treatment.
[0041] [7] The method for producing a cyclized peptide according to any one of [1] to [6], wherein
[0042] In step (1-B), the fully protected peptide is subjected to temporary SS-reaction to obtain a temporary SS-reaction peptide mixture, and then,
[0043] In step (1-A), the protective groups of all functional groups of the temporarily SS-formed peptide mixture except the SH group protected by forming a temporary SS bond are deprotected to obtain an S-protected peptide;
[0044] [8] The method for producing a cyclized peptide according to [7], wherein the protecting group of the SH group in the fully protected peptide is a protecting group other than an S-type protecting group;
[0045] [9] The method for producing a cyclized peptide according to [8], wherein the protecting group of the SH group in the fully protected peptide is a trityl group (Trt group), an acetylaminomethyl group (Acm group), a benzyl group (Bzl group), a 4-methylbenzyl group (4-MeBzl group), or a 4-methoxybenzyl group (MBzl group);
[0046]
[10] The method for producing a cyclized peptide according to any one of [7] to [9], wherein the temporary SS-replacement is performed by iodine treatment or thallium (III) trifluoroacetate treatment;
[0047]
[11] The method for producing a cyclized peptide according to
[10] , wherein the temporary SS-reaction is performed by iodine treatment.
[0048]
[12] The method for producing a cyclized peptide according to any one of [1] to [4], wherein
[0049] In step (1-A), the protecting groups of all functional groups other than the SH group of the fully protected peptide are deprotected, and subsequently or simultaneously,
[0050] In step (1-B), the deprotected peptide is subjected to temporary SS-reaction to obtain a temporary SS-reaction peptide mixture, thereby obtaining an S-protected peptide;
[0051]
[13] The method for producing a cyclized peptide according to
[12] , wherein the protecting group of the SH group of the fully protected peptide is a protecting group other than an S-type protecting group;
[0052]
[14] The method for producing a cyclized peptide according to
[13] , wherein the protecting group of the SH group in the fully protected peptide is an acetylaminomethyl group (Acm group), a tert-butyl group (t-Bu group), a trityl group (Trt group), a benzyl group (Bzl group), a 4-methylbenzyl group (4-MeBzl group), or a 4-methoxybenzyl group (MBzl group);
[0053]
[15] The method for producing a cyclized peptide according to any one of
[12] to
[14] , wherein temporary SS-reduction is performed by iodine treatment, DMSO / TFA treatment, or thallium (III) trifluoroacetate treatment;
[0054]
[16] The method for producing a cyclized peptide according to
[15] , wherein the temporary SS-reaction is performed by iodine treatment.
[0055]
[17] The method for producing a cyclized peptide according to any one of [1] to [4], wherein
[0056] a) 1) In step (1-A), all protective groups of the fully protected peptide except the SH group are deprotected, and then,
[0057] 2) Remove the SH protecting group, and then
[0058] 3) in step (1-B), subjecting the peptide to temporary SS to obtain a temporary SS-treated peptide mixture; or
[0059] b) 1) removing the protecting groups of the SH groups of the fully protected peptide, and then,
[0060] 2) In step (1-B), the peptide mixture is temporarily SS-treated to obtain a temporarily SS-treated peptide mixture, and then
[0061] 3) in step (1-A), the protective groups of all functional groups of the temporarily SS-modified peptide mixture except the SH group protected by forming a temporary SS bond are deprotected to obtain an S-protected peptide;
[0062]
[18] The method for producing a cyclized peptide according to
[17] , wherein the protecting group of the SH group is a protecting group other than an S-type protecting group;
[0063]
[19] The method for producing a cyclized peptide according to
[18] , wherein the protecting group of the SH group is a phenylacetylaminomethyl group (Phacm group), a 4-methoxybenzyl group (MBzl group), or a monomethoxytrityl group (MMTrt group);
[0064]
[20] The method for producing a cyclized peptide according to
[19] , wherein the removal of the protecting group of the SH group is carried out by the following treatment:
[0065] Treatment with aqueous solution in the presence of penicillin amide hydrolase (PGA),
[0066] Use DDQ treatment, or
[0067] Use weak acid treatment;
[0068]
[21] The method for producing a cyclized peptide according to any one of
[17] to
[20] , wherein the temporary SS-reaction is performed by iodine treatment, Npys-OMe treatment, or thallium (III) trifluoroacetate treatment;
[0069]
[22] The method for producing a cyclized peptide according to
[21] , wherein the temporary SS-reaction is performed by iodine treatment.
[0070]
[23] The method for producing a cyclized peptide according to any one of [1] to [3], wherein in step (1-B), the protection of all SH groups by forming temporary SS bonds is achieved by forming temporary SS bonds with S-type protecting groups;
[0071]
[24] The method for producing a cyclized peptide according to
[23] , wherein in step (1-B), the protection of all SH groups based on the formation of temporary SS bonds is achieved by reprotecting the SH group's protecting group with an S-type protecting group via a protecting group other than an S-type protecting group;
[0072]
[25] The method for producing a cyclized peptide according to
[23] or
[24] , wherein the S-type protecting group is 3-nitro-2-pyridinesulfinyl (Npys group), tert-butylthiol (S-tBu group), or ethylthiol (S-Et group);
[0073]
[26] The method for producing a cyclized peptide according to any one of [1] to [3] or
[23] to
[25] , wherein
[0074] In step (1-B), the protecting group of the SH group of a linear peptide having two or more SH groups protected by protecting groups as functional groups on the peptide, wherein the N-terminal amino group may be protected and the C-terminal carboxyl group and all other functional groups on the peptide are protected, is re-protected with an S-type protecting group, or,
[0075] Pre-protected with an S-type protecting group, thereby obtaining a peptide in which all SH groups are protected by forming temporary SS bonds with the S-type protecting groups;
[0076] In step (1-A), the protecting groups of all functional groups of the peptide except the SH group temporarily protected by the SS bond are deprotected to obtain an S-protected peptide.
[0077]
[27] The method for producing a cyclized peptide according to any one of [1] to
[26] , wherein the deprotection is carried out in the absence of a reducing agent.
[0078]
[28] The method for producing a cyclized peptide according to any one of [1] to
[27] , wherein the folding step under redox conditions in step (2) is carried out in an aqueous solution at a pH of 6 or higher;
[0079]
[29] The method for producing a cyclized peptide according to any one of [1] to
[28] , wherein the folding step under redox conditions in step (2) is performed in the co-presence of an oxidizing agent and a reducing agent.
[0080]
[30] The method for producing a cyclized peptide according to any one of [1] to
[29] , wherein the number of SH groups present as functional groups on the S-protected peptide is 2;
[0081]
[31] The method for producing a cyclized peptide according to any one of [1] to
[29] , wherein the number of SH groups as functional groups on the S-protected peptide is 4 or more;
[0082]
[32] The method for producing a cyclized peptide according to any one of [1] to
[31] , wherein the number of SH groups as functional groups on the S-protected peptide is an even number.
[0083] Effects of the Invention
[0084] In the present invention, the SH group can be protected by temporarily forming an SS bond, thereby efficiently obtaining a cyclized peptide in the folding step. In the present invention, the cyclization reaction can be efficiently carried out even under relatively high concentration conditions, and thus the problem (technical problem) of the conventional method can be overcome, such as the decrease in yield due to alkylation of the residues of various protecting groups after SH group deprotection, and the decrease in yield of the target cyclization reaction due to by-product impurities. The present invention is also very excellent from the viewpoint of production efficiency because the cyclization reaction can be efficiently carried out even under relatively high concentration conditions.
[0085] Brief description of the attached figure
[0086] Figure 1 The following is an overview of the embodiments of the present invention. "Embodiment 1-1", "Embodiment 1-2", "Embodiment 1-3" and "Embodiment 2-1" in the figure correspond to the embodiments in step (1-A) and step (1-B). DETAILED DESCRIPTION
[0087] As described above, the basic embodiment of the present invention is a method for producing a cyclized peptide having a cross-linked structure based on intramolecular SS bonds, comprising the following steps.
[0088] [1] A method for producing a cyclized peptide, comprising:
[0089] (1-A) a step of deprotecting the protecting groups of all functional groups of a linear peptide having two or more SH groups as functional groups on the peptide, wherein all SH groups are protected, the N-terminal amino group may be protected, and the C-terminal carboxyl group and other functional groups on the peptide are all protected ("fully protected peptide");
[0090] (1-B) a step of protecting all SH groups in a linear peptide having two or more SH groups as functional groups on the peptide by forming temporary SS bonds;
[0091] as well as
[0092] (2) A step in which a peptide having two or more SH groups as functional groups on the peptide obtained by the above steps (1-A) and (1-B), all of which are protected by forming temporary SS bonds and all protecting groups of other functional groups on the peptide are deprotected ("S-protected peptide"), is subjected to a folding step under redox conditions, and a cyclized peptide is obtained by re-forming SS bonds within the peptide molecule.
[0093] Hereinafter, the present invention will be described in detail. Unless otherwise specified in the text, all technical terms and scientific terms used in this specification have the same meaning as those commonly understood by those skilled in the art of the technical field to which the present invention belongs. Any method and material that is the same or equivalent to the content recorded in this specification can be used in the implementation or test of the present invention, and the preferred method and material are described below. For all publications and patents mentioned in this specification, for example, the constructions and methodology recorded in the publications that can be used in relation to the described invention can be incorporated into this specification as a reference for the purpose of recording and revealing.
[0094] [Regarding Step (1-A) and Step (1-B)]
[0095] The "fully protected peptide" used in this step can be produced by the following method: corresponding to the sequence of the target cyclized peptide, using raw materials known to those skilled in the art, a structural unit such as an amino acid in which the terminal amino group and the terminal carboxyl group are protected by a protecting group known in the art and the functional group containing the SH group is protected by an appropriate protecting group is produced or purchased, and a deprotection reaction and a peptide chain extension reaction are repeatedly carried out according to a method known per se or a method based thereon. The protection of the SH group can also be carried out by protecting the SH group by forming a temporary SS bond after peptide synthesis, which is described below.
[0096] The target cyclized peptide may be either a naturally occurring peptide or a non-naturally occurring peptide.
[0097] The amino acid etc. that become the structural unit of the peptide manufactured by the method of the present invention are compounds having an amino group and a carboxyl group in the same molecule, and may be a natural amino acid or a non-natural amino acid, and may also be an L-type or a D-type, or may be a racemate. In addition, the structural unit is not limited to amino acids, and may be a compound applicable in the synthesis of other peptides (hereinafter referred to as an amino acid analog). If it is a person skilled in the art, such an amino acid analog can be appropriately selected and manufactured or purchased according to a method known per se or based on them.
[0098] Examples of the SH group as a functional group on the peptide include SH groups possessed by a cysteine residue, a homocysteine residue, a 3-mercaptopropionyl group, and the like, but the present invention is not limited thereto.
[0099] The SH group as a functional group on the peptide is not particularly limited to any residue as long as it exists in the peptide sequence, and can be arranged at any position at the end or in the middle of the peptide sequence, or can be adjacent to each other. In addition, it also includes the case where the SH group exists across multiple chains, such as insulin generated by cleavage from proinsulin.
[0100] The protecting group for the N-terminal amino group, the protecting group for the C-terminal carboxyl group, the amino acid having an SH group as a functional group on the peptide, or the protecting group for the functional group on the peptide of the structural unit other than an amino acid analogue can be selected from those commonly used in the technical field, and a protecting group suitable for achieving the purpose of step (1-A) can be selected based on the selection of the protecting group for the SH group in step (1-A).
[0101] This step (1-A) refers to the step of deprotecting the protecting groups of all functional groups of the "fully protected peptide" except the protected SH group (including the pseudo-solid-phase protecting groups and solid-phase carriers described later). The deprotection in this step (1-A) also includes cutting out the pseudo-solid-phase protecting groups and the solid-phase carrier. The deprotection in this step (1-A) can be carried out by the methods commonly used in the technical field according to the protecting groups used. During the deprotection here, it is necessary that the protecting group of the SH group will not be removed at the same time. Therefore, it is ideal to select an appropriate deprotection method according to the protecting group of the SH group. In particular, when the protection of the SH group is achieved by a temporary SS bond described later, it is appropriate to select a method that can be deprotected in the absence of a reducing agent. More specific deprotection methods are described below.
[0102] This step (1-B) is a step of protecting all SH groups in a linear peptide having two or more SH groups as functional groups on the peptide by forming temporary SS bonds.
[0103] The formation of temporary SS bond is performed by forming a temporary SS bond with an S-type protecting group or forming a temporary SS bond by temporary SSization. In addition, the protecting group of SH group is also included, and the details thereof are described below according to the embodiment.
[0104] The formation of a temporary SS bond in step (1-B) is carried out at an appropriate time before, after, or simultaneously with the deprotection of the protecting groups of all functional groups other than the SH group (including the pseudo solid phase protecting groups described later) (step (1-A)). The relationship between step (1-A) and step (1-B) is appropriately determined according to the relationship between the protecting group of the SH group used, the reaction mode for forming the temporary SS bond, the deprotection conditions of the protecting groups other than the SH group, etc., and a preferred specific embodiment is described below.
[0105] Step (1-A) and step (1-B) can be carried out under any conditions of solid phase conditions or liquid phase conditions (including pseudo-solid phase conditions using pseudo-solid phase protecting groups). Those skilled in the art can appropriately select solid phase or liquid phase (pseudo-solid phase using pseudo-solid phase protecting groups) conditions according to the structure of the target cyclized peptide and the synthesis strategy such as the production purpose (production scale, etc.).
[0106] When step (1-A) and step (1-B) are carried out under solid phase conditions, at least one of the functional groups on the peptide, such as the terminal carboxyl group or a functional group on the peptide (e.g., a carboxyl group), is supported on a solid phase carrier by a conventional method in peptide synthesis under solid phase conditions.
[0107] The solid phase carrier can be any solid phase carrier known in the art suitable for solid phase synthesis. In this specification, the term "solid phase" includes a functional linker or handle group commonly used by peptides combined or connected with the above-mentioned solid phase carrier, and the meaning of such a linker is also included when "solid phase" is mentioned in this article (context). Examples of solid phases include: polystyrene supports (for example, further functionalized by p-methylbenzyl-hydrylamine), or rigid functionalized supports such as polydimethylacrylamide (pepsin K), silica or microporous glass encapsulated with diatomaceous earth. The resin matrix of the solid phase can be composed of amphiphilic polystyrene-PEG resin or PEG-polyamide or PEG-polyester resin. As a solid phase carrier, it also includes, for example, Wang-PEG resin (Alko-PEG resin), SAL-PEG resin or Rink-amide PEG resin.
[0108] Various protecting groups used in the peptide of the present invention are described below. Each protecting group can be introduced into each functional group according to a method commonly performed in the art.
[0109] Examples of the protecting group in the case where the SH group in the “fully protected peptide” is protected by a protecting group include protecting groups other than S-type protecting groups (e.g., tert-butyl (t-Bu group), triphenylmethyl (trityl: Trt group), methyltrityl, methoxytrityl, monomethoxytrityl (MMTrt group), adamantyl (Ad group), acetylaminomethyl (Acm group), trimethylacetylaminomethyl, phenylacetylaminomethyl (Phacm group), benzyl (Bzl group), 4- -methylbenzyl (4-MeBzl group), 3-methylbenzyl, 2-methylbenzyl, 4-methoxybenzyl (MBzl group), 3-methoxybenzyl, 2-methoxybenzyl, 2,4,6-trimethoxybenzyl, Dabsyl (Dbs group: 4-dimethylaminoazobenzene-4'-sulfonyl group), etc.), and S-type protecting groups (for example, 3-nitro-2-pyridinesulfinyl (Npys group), tert-butylthiol (S-tBu group), ethylthiol (S-Et group), etc.). It is not limited to these groups. As long as a person skilled in the art can select an appropriate protecting group for the SH group according to the overall synthetic strategy when implementing the present invention, the preferred embodiment is described below.
[0110] Hereinafter, the protecting groups of the functional groups other than the SH group possessed by the “fully protected peptide” will be described.
[0111] (Protective group of N-terminal amino group)
[0112] Although not essential for carrying out step (1-A), examples of the protecting group (temporary protecting group) for the N-terminal amino group include a 9-fluorenylmethoxycarbonyl group (hereinafter also referred to as an Fmoc group) and a tert-butoxycarbonyl group (hereinafter also referred to as a Boc group). An Fmoc group is preferred.
[0113] (Protective group for C-terminal carboxyl group)
[0114] Examples of the protecting group for the C-terminal carboxyl group include an ester type protecting group, an amide type protecting group, and a hydrazide type protecting group.
[0115] As the ester type protecting group, preferably substituted or unsubstituted alkyl esters and substituted or unsubstituted aralkyl esters are used. As the substituted or unsubstituted alkyl esters, preferably methyl esters, ethyl esters, tert-butyl esters, cyclohexyl esters, trichloroethyl esters, acetophenone esters are used. As the substituted or unsubstituted aralkyl esters, preferably benzyl esters, p-nitrobenzyl esters, p-methoxybenzyl esters, diphenylmethyl esters, 9-fluorenylmethyl (Fm) esters, 4-pyridylmethyl (Pic) esters are used.
[0116] As the amide type protecting group, unsubstituted amide, primary amide such as N-methylamide, N-ethylamide, and N-benzylamide, and secondary amide such as N,N-dimethylamide, pyrrolidinylamide, and piperidinylamide are preferably used.
[0117] As the hydrazide type protecting group, unsubstituted hydrazide, N-phenylhydrazide, N,N′-diisopropylhydrazide and the like are preferably used.
[0118] (Protective group of functional group on peptide)
[0119] Examples of the protecting groups for the functional groups on the peptide include those described in “Fundamentals and Experiments of Peptide Synthesis”, published by Maruzen Co., Ltd. (1985), and “Protective Groups in Organic Synthesis”, 3rd edition, published by John Willy & Sons (1999).
[0120] When the functional group on the peptide is an amino group, examples thereof include a carbamate type protecting group, an acyl type protecting group, and a sulfonyl type protecting group.
[0121] As the carbamate type protecting group, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl (Boc) and the like can be used. Among them, the Boc group can be selectively deprotected under mild acidic conditions and is therefore particularly preferably used.
[0122] As the acyl type protecting group, for example, a formyl group, an acetyl group, a trifluoroacetyl group and the like can be preferably used.
[0123] As the sulfonyl type protecting group, for example, p-toluenesulfonyl (Ts), p-tolylmethylsulfonyl, 4-methoxy-2,3,6-trimethylbenzenesulfonyl and the like can be preferably used.
[0124] When the functional group on the peptide is a carboxyl group, examples of the protecting groups include the same protecting groups as those mentioned above as the protecting groups for the C-terminal carboxyl group.
[0125] When the functional group on the peptide is a hydroxyl group (including a phenolic hydroxyl group), examples thereof include an alkyl type protecting group, an alkoxyalkyl type protecting group, an acyl type protecting group, and an alkylsilyl type protecting group.
[0126] Examples of the alkyl type protecting group include methyl, ethyl, and tert-butyl groups.
[0127] Examples of the alkoxyalkyl type protecting group include a methoxymethyl group (MOM group), a 2-tetrahydropyranyl group (THP group), and an ethoxyethyl group (EE group).
[0128] Examples of the acyl type protecting group include acetyl, pivaloyl, and benzoyl.
[0129] Examples of the alkylsilyl type protecting group include trimethylsilyl (TMS group), triethylsilyl (TES group), tert-butyldimethylsilyl (TBS group or TBDMS group), triisopropylsilyl (TIPS group), and tert-butyldiphenylsilyl (TBDPS group).
[0130] Other functional groups may also be protected by conventional protecting groups in the art. For example, the guanidine group of arginine may be protected by a p-toluenesulfonyl group. The imidazole group of histidine may be protected by a trityl group, a benzyloxymethyl group, etc. In addition, the indole group of tryptophan may be protected by a formyl group.
[0131] The protecting groups of the functional groups on the peptides have been described above, but those skilled in the art can carry out this step by appropriately selecting the protecting groups according to the overall synthetic strategy in the art (e.g., Fmoc / tBu strategy, tBu / Bzl strategy, Bzl / tBu strategy, etc.), wherein the Fmoc / tBu strategy is preferred.
[0132] When the present invention is carried out under liquid phase conditions, it is desirable that when the C-terminal carboxyl group and the functional group on the peptide are carboxyl groups, at least one of the carboxyl groups is protected. As the protecting group of the carboxyl group, the protecting groups (ester type protecting groups, amide type protecting groups, hydrazide type protecting groups, etc.) mentioned in the above-mentioned "protecting group of the C-terminal carboxyl group" can be cited. Among them, the ester type protecting group is preferably used. As the ester type protecting group, substituted or unsubstituted alkyl esters, substituted or unsubstituted aralkyl esters are preferably used. As substituted or unsubstituted alkyl esters, methyl esters, ethyl esters, tert-butyl esters, cyclohexyl esters, trichloroethyl esters, acetophenone esters, etc. are preferably used. As substituted or unsubstituted aralkyl esters, benzyl esters, p-nitrobenzyl esters, p-methoxybenzyl esters, diphenylmethyl esters, 9-fluorenylmethyl (Fm) esters, 4-pyridylmethyl (Pic) esters, etc. are preferably used. Tert-butyl esters, benzyl esters, etc. are particularly preferred.
[0133] (Pseudo solid phase protecting group)
[0134] When the present invention is carried out under liquid phase conditions, in order to simplify purification, when the C-terminal carboxyl group and the functional group on the peptide are carboxyl groups, at least one of the carboxyl groups may be protected by a pseudo-solid phase protecting group (hereinafter sometimes referred to as "anchor" in this specification) as required. The purification method of the peptide using the pseudo-solid phase protecting group is not particularly limited, and can be carried out according to a method known per se (see Japanese Patent Publication No. 2000-44493, International Publication No. 2006 / 104166, International Publication No. 2007 / 034812, International Publication No. 2007 / 122847, International Publication No. 2010 / 113939, International Publication No. 2010 / 104169, International Publication No. 2011 / 078295, International Publication No. 2012 / 029794, etc.) or a method based thereon. Here, the pseudo solid phase protecting group refers to a group including an anchor having a molecular weight of 300 or more (e.g., a benzyl compound, a diphenylmethane compound, or a fluorene compound) which is soluble in a halogen solvent or an ether solvent and insoluble in a polar solvent, and the group is a group that can condense with a carboxyl group.
[0135] One embodiment of the above-mentioned anchor having a molecular weight of 300 or more and being soluble in a halogen solvent or an ether solvent and insoluble in a polar solvent is a compound represented by the following formula (I). Among them, a compound having a molecular weight of 400 or more is preferred.
[0136] Formula (I):
[0137] [Chemical formula 1]
[0138]
[0139] In the formula,
[0140] R 1 is a hydrogen atom, or R b In the case of a group represented by the following formula (a), R 3 Together they represent a single bond, and can form a fluorene ring together with ring A and ring B;
[0141] p R 2 Each independently represents an organic group having an aliphatic hydrocarbon group;
[0142] p represents an integer from 1 to 4;
[0143] Ring A has p ORs 2 In addition, it may further have a C selected from halogen atoms, which may be substituted by halogen atoms. 1-6 Alkyl, and C 1-6 Substituents in an alkoxy group;
[0144] R arepresents a hydrogen atom or a phenyl group which may be substituted by a halogen atom; and
[0145] R b represents a hydrogen atom or a group represented by the formula (a).
[0146] [Chemical formula 2]
[0147]
[0148] (Where, * Indicates the binding position,
[0149] r represents an integer from 0 to 4,
[0150] r R 4 Each independently represents an organic group having an aliphatic hydrocarbon group,
[0151] R 3 represents a hydrogen atom, or with R 1 Together they represent a single bond, and may form a fluorene ring together with ring A and ring B, and
[0152] Ring B has r ORs 4 In addition, it may further have a C selected from halogen atoms, which may be substituted by halogen atoms. 1-6 Alkyl, and C 1-6 substituents in the alkoxy group; and Y represents a hydroxyl group, NHR, or a halogen atom, and R represents a hydrogen atom, an alkyl group, or an aralkyl group).
[0153] The anchor represented by the formula (I) is bonded to the compound to be protected. That is, the anchor in which Y is a hydroxyl group, -NHR group, or halogen atom is condensed with the carboxyl group of the C-terminus of an amino acid or a peptide to protect the compound.
[0154] In the present specification, examples of the "alkyl group" represented by R include linear or branched C 1-30 Alkyl, preferably C 1-10 Alkyl, preferably C 1-6 Preferred specific examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like, with methyl and ethyl being particularly preferred.
[0155] In the present specification, examples of the "aralkyl group" represented by R include C 7-30 Arylalkyl, preferably C 7-20 Arylalkyl, preferably C 7-16 Arylalkyl (C 6-10 Aryl-C 1-6Specific preferred examples include benzyl, 1-phenylethyl, 2-phenylethyl, 1-phenylpropyl, naphthylmethyl, 1-naphthylethyl, 1-naphthylpropyl and the like, and benzyl is particularly preferred.
[0156] R is preferably a hydrogen atom, C 1-6 Alkyl or C 7-16 The aralkyl group is more preferably a hydrogen atom, a methyl group, an ethyl group or a benzyl group, particularly preferably a hydrogen atom.
[0157] In the present specification, the "halogen atom" means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom. In the present specification, the "halogen atom" represented by Y is preferably a chlorine atom, a bromine atom or an iodine atom, more preferably a bromine atom.
[0158] In this specification, R 2 or R 4 The "organic group having an aliphatic hydrocarbon group" referred to herein means a monovalent organic group having an aliphatic hydrocarbon group in its molecular structure.
[0159] The "aliphatic hydrocarbon group" in the "organic group having an aliphatic hydrocarbon group" refers to a straight-chain or branched saturated or unsaturated aliphatic hydrocarbon group, preferably an aliphatic hydrocarbon group having 5 or more carbon atoms, more preferably an aliphatic hydrocarbon group having 5 to 60 carbon atoms, further preferably an aliphatic hydrocarbon group having 5 to 30 carbon atoms, and particularly preferably an aliphatic hydrocarbon group having 10 to 30 carbon atoms;
[0160] The site of the "aliphatic hydrocarbon group" in the "organic group having an aliphatic hydrocarbon group" is not particularly limited, and it may be present at a terminal (monovalent group) or at another site (for example, a divalent group).
[0161] Examples of the “aliphatic hydrocarbon group” include monovalent groups such as alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl, and divalent groups derived therefrom. Preferred examples include monovalent groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, amyl, hexyl, octyl, decyl, dodecyl, lauryl, tridecyl, myristyl, cetyl, stearyl, eicosyl, behenyl, oleyl, and isostearyl, and divalent groups derived therefrom.
[0162] The part other than the "aliphatic hydrocarbon group" in the "organic group having an aliphatic hydrocarbon group" can be set arbitrarily. For example, as a connector, there can be a part having -O-, -S-, -COO-, -OCONH-, and -CONH-, as well as a hydrocarbon group (monovalent group or divalent group). As the "hydrocarbon group", for example, aliphatic hydrocarbon groups, aromatic aliphatic hydrocarbon groups, monocyclic saturated hydrocarbon groups and aromatic hydrocarbon groups can be cited. Specifically, monovalent groups such as alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl and divalent groups derived therefrom can be used. As the "alkyl", for example, C1-6 Examples of the alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl and hexyl. 2-6 Examples of the "alkynyl" include vinyl, 1-propenyl, allyl, isopropenyl, butenyl, and isobutenyl. "Alkynyl" is preferably C 2-6 Examples of the "cycloalkyl" include ethynyl, propargyl, and 1-propynyl. 3-6 Cycloalkyl, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. "Aryl" is preferably, for example, C 6-14 Aryl, for example, phenyl, 1-naphthyl, 2-naphthyl, biphenyl, 2-anthryl, etc. are mentioned. Among them, C 6-10 The aryl group is preferably a phenyl group. 7-20 Aralkyl groups include, for example, benzyl, 1-phenylethyl, 2-phenylethyl, 1-phenylpropyl, naphthylmethyl, 1-naphthylethyl, 1-naphthylpropyl, etc. Among them, C 7-16 Aralkyl (C 6-10 Aryl-C 1-6 The "hydrocarbon group" may be substituted with a substituent selected from a halogen atom (chlorine atom, bromine atom, fluorine atom, iodine atom), an alkyl group having 1 to 6 carbon atoms which may be substituted with one or more halogen atoms, an oxo group, or the like.
[0163] The OR in the above formula (I) is 2 Base OR 4 The "organic group having an aliphatic hydrocarbon group" may have a plurality of "aliphatic hydrocarbon groups" by branching, etc. When a plurality of "aliphatic hydrocarbon groups" exist in the "organic group having an aliphatic hydrocarbon group", these groups may be the same or different.
[0164] As R in the above formula (I) 2 or R 4 The lower limit of the total number of carbon atoms in the "organic group having an aliphatic hydrocarbon group" is preferably 5, more preferably 10, further preferably 12, further preferably 14, particularly preferably 16, and particularly preferably 20. 2 or R 4 The upper limit of the total number of carbon atoms in the "organic group having an aliphatic hydrocarbon group" is preferably 200, more preferably 150, further preferably 120, further more preferably 100, particularly preferably 80, particularly preferably 60, further particularly preferably 40, and most preferably 30. The larger the number of carbon atoms, the better the crystallinity of the compound represented by formula (I) in a polar solvent even when the peptide chain is long.
[0165] As “OR 2 "OR 4 Preferred specific examples of the "OR" group include dodecyloxy, cetyloxy, octadecyloxy, behenyloxy, behenyloxy-dodecyloxy, triacontyloxy and the like. 2 "OR 4 There are p or r " groups in total, p is an integer of 1 to 4, r is an integer of 0 to 4, p is preferably 2 or 3, and r is preferably an integer of 0 to 2.
[0166] Preferred specific examples of the substituent that may be present in ring A or ring B in the above formula (I) include C 1-6 Alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, etc.) 1-4 Alkoxy), C 1-6 Alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.) 1-6 Alkyl, trifluoromethyl, trichloromethyl and other halogen-substituted C 1-6 alkyl), or a halogen atom, wherein preferably C 1-6 Alkoxy.
[0167] A preferred form of the anchor represented by the above formula (I) may be the following compound: In the formula (I),
[0168] Y is a hydroxyl group,
[0169] R 1 is a hydrogen atom,
[0170] R 2 and / or R 4 is an aliphatic hydrocarbon group having 5 to 60 carbon atoms,
[0171] p is an integer from 1 to 3,
[0172] r is an integer from 0 to 2.
[0173] Another preferred form of the anchor represented by the above formula (I) may be the following compound: In the formula (I),
[0174] Y is a hydroxyl group,
[0175] R a , R b , and R 1 The same is a hydrogen atom,
[0176] R 2 is an aliphatic hydrocarbon group having 5 to 60 carbon atoms,
[0177] p is an integer from 1 to 3.
[0178] Another preferred form of the anchor represented by the above formula (I) may be the following compound: In the formula (I),
[0179] Y is a hydroxyl group,
[0180] R a , R b , and R 1 The same is a hydrogen atom,
[0181] R 2 represents an alkyl group having 10 to 40 carbon atoms,
[0182] p is 2 or 3.
[0183] Another preferred form of the anchor represented by the above formula (I) may be the following compound: In the formula (I),
[0184] Y is a hydroxyl group,
[0185] R a , R b , and R 1 The same is a hydrogen atom,
[0186] R 2 represents an alkyl group having 12 to 30 carbon atoms,
[0187] p is 2 or 3.
[0188] Another preferred form of the anchor represented by the above formula (I) may be the following compound: In the formula (I),
[0189] Y is a hydroxyl group,
[0190] R a , R b , and R 1 The same is a hydrogen atom,
[0191] R 2 is a benzyl group having 1 to 3 alkoxy groups having 12 to 30 carbon atoms,
[0192] p is an integer from 1 to 3.
[0193] Another preferred form of the anchor represented by the above formula (I) may be the following compound: In the formula (I),
[0194] Y is a hydroxyl group,
[0195] R a , R b , and R 1 The same is a hydrogen atom,
[0196] R2 is a cyclohexylmethyl group having 1 to 3 alkoxy groups having 12 to 30 carbon atoms,
[0197] p is an integer from 1 to 3.
[0198] Preferred examples of the anchor having a molecular weight of 300 or more and being soluble in a halogen solvent or an ether solvent and insoluble in a polar solvent in the present invention include the following anchors:
[0199] 3,4,5-Tri(octadecyloxy)benzyl alcohol,
[0200] 2,4-di(docosyloxy)benzyl alcohol,
[0201] 4-methoxy-2-[3',4',5'-tri(octadecyloxy)benzyloxy]benzyl alcohol,
[0202] 4-methoxy-2-[3',4',5'-tri(octadecyloxy)cyclohexylmethoxy]benzyl alcohol,
[0203] 2-methoxy-4-[3',4',5'-tri(octadecyloxy)cyclohexylmethoxy]benzyl alcohol,
[0204] 4-[3',4',5'-tri(octadecyloxy)cyclohexylmethoxy]benzyl alcohol,
[0205] 3,5-dimethoxy-4-[3',4',5'-tri(octadecyloxy)cyclohexylmethoxy]benzyl alcohol,
[0206] 2,4-Di(dodecyloxy)benzyl alcohol,
[0207] 3,4,5-Tris(octadecyloxy)benzylamine,
[0208] Bis(4-docosyloxyphenyl)methanol,
[0209] Bis(4-docosyloxyphenyl)methylamine, and
[0210] 2-(12-Docosanyloxy-dodecyloxy)-9-(3-fluorophenyl)-9-bromofluorene.
[0211] As other preferred pseudo solid phase protecting groups, the following groups can be mentioned.
[0212] Examples include branched aromatic compounds represented by formula (II):
[0213] [Chemical formula 3]
[0214]
[0215] [Wherein,
[0216] k Qs represent a single bond, or represent -O-, -S-, -C(=O)O-, -C(=O)NH-, or -NH-;
[0217] k R a Each independently represents an organic group having at least one aliphatic hydrocarbon group having one or more branches, a total number of branches of 3 or more, and a total number of carbon atoms of 14 or more and 300 or less;
[0218] k represents an integer from 1 to 4;
[0219] R 1 is a hydrogen atom, or Z is a group represented by the following formula (a), and R 2 Together they represent a single bond and can form a fluorene ring together with ring B;
[0220] Ring A has R1, k QR a , and C(X)(Y)Z, may further have a C selected from halogen atoms, which may be substituted by one or more halogen atoms. 1-6 Alkyl, and C 1-6 Substituents in an alkoxy group;
[0221] X represents a hydrogen atom or a phenyl group;
[0222] Y represents a hydroxyl group or an -NHR group, and R represents a hydrogen atom, an alkyl group or an aralkyl group; and
[0223] Z represents a hydrogen atom or a group represented by the formula (a).
[0224] [Chemical formula 4]
[0225]
[0226] (In formula (a), * Indicates the binding position,
[0227] m represents an integer from 0 to 4,
[0228] m Qs have the same meaning as above.
[0229] m R b Each independently represents an organic group having at least one aliphatic hydrocarbon group having one or more branches, a total number of branches of 3 or more, and a total number of carbon atoms of 14 or more and 300 or less,
[0230] R 2 represents a hydrogen atom, or with R 1 Together they represent a single bond and can form a fluorene ring together with ring A, and
[0231] Ring B has m QRs b, and R2, may further have a C selected from halogen atoms, which may be substituted by one or more halogen atoms 1-6 Alkyl, and C 1-6 substituents in an alkoxy group);
[0232] The R a and R b The organic group having at least one aliphatic hydrocarbon group having one or more branches, a total number of branches of 3 or more, and a total number of carbon atoms of 14 or more and 300 or less is a group having three or more identical or different divalent groups represented by formula (b).
[0233] [Chemical formula 5]
[0234]
[0235] (In formula (b), * represents the bonding position with the adjacent atoms,
[0236] R3 and R4 are independently a hydrogen atom or a C 1-4 alkyl,
[0237] X1 represents a single bond, C 1-4 an alkylene group or an oxygen atom,
[0238] wherein R3 and R4 are different from each other and are hydrogen atoms)].
[0239] More preferably, the following compounds are mentioned.
[0240] Aromatic compounds containing branches selected from the following compounds:
[0241] 2,4-di(2',3'-dihydrophytyloxy)benzyl alcohol,
[0242] 3,5-Di(2',3'-dihydrophytyloxy)benzyl alcohol,
[0243] 4-(2',3'-dihydrophytyloxy)benzyl alcohol,
[0244] 1-[(2-chloro-5-(2',3'-dihydrophytyloxy)phenyl)]-1-phenylmethanamine,
[0245] 3,4,5-Tris(2',3'-dihydrophytyloxy)benzyl alcohol,
[0246] 3,4,5-Tris(2',3'-dihydrophytyloxy)benzylamine,
[0247] 4-(2',3'-dihydrophytyloxy)benzylamine,
[0248] 2-[3',4',5'-tri(2",3"-dihydrophytyloxy)benzyloxy]-4-methoxybenzyl alcohol,
[0249] 4-(2',3'-dihydrophytyloxy)-2-methoxybenzyl alcohol,
[0250] 4-(2',3'-dihydrophytyloxy)-2-methoxybenzylamine,
[0251] 4-(2',3'-dihydrophytyloxy)-2-methylbenzyl alcohol,
[0252] 4-(2',3'-dihydrophytyloxy)-2-methylbenzylamine,
[0253] 2,2,4,8,10,10-hexamethyl-5-dodecanoic acid (4-hydroxymethyl)phenylamide,
[0254] 4-(3,7,11-trimethyldodecyloxy)benzyl alcohol,
[0255] 2-(3,7,11-trimethyldodecyloxy)-9-phenylfluoren-9-ol,
[0256] The compounds represented by the following [Chemical Formula 6] to [Chemical Formula 9].
[0257] In the form:
[0258] [Chemical formula 6]
[0259]
[0260] (where n 16 It represents the compound represented by 23 or 34).
[0261] In the form:
[0262] [Chemical formula 7]
[0263]
[0264] (where n 17 It represents the compound represented by 23 or 34).
[0265] In the form:
[0266] [Chemical formula 8]
[0267]
[0268] (where n 18 It represents the compound represented by 5 or 7).
[0269] And the formula:
[0270] [Chemical formula 9]
[0271]
[0272] Represents the compound.
[0273] Another preferred pseudo solid phase protecting group includes: di(4-docosyloxyphenyl)methylamine (NHCH2(Phe(4-OC 22 H 45 ))2) etc.
[0274] The method for producing the anchor is not particularly limited, and the anchor can be produced from a raw material compound according to a known method (see Japanese Patent Application Publication No. 2000-44493, International Publication No. 2006 / 104166, International Publication No. 2007 / 034812, International Publication No. 2007 / 122847, International Publication No. 2010 / 113939, International Publication No. 2010 / 104169, International Publication No. 2011 / 078295, International Publication No. 2012 / 029794, etc.), or a method based thereon. The compound used as the raw material compound, for example, the group R of formula (I) 2 or R 4 The corresponding halides and the like are available as commercial products, or can be produced by methods known per se or methods based thereon.
[0275] The deprotection of the protecting group of the functional group other than the SH group possessed by the fully protected peptide will be described below.
[0276] The deprotection of the protecting group in this step (1-A) can be carried out by a known deprotection method according to the type of the protecting group to be deprotected without particular limitation, and it is necessary to select conditions that do not adversely affect the protecting group of the SH group and the protection of the SH group based on the formation of a temporary SS bond. For example, it is preferably carried out in the absence of a reducing agent. Those skilled in the art can appropriately select appropriate conditions based on the overall synthesis strategy.
[0277] For example, in the case of a lower alkyl group such as Me or Et, deprotection can be carried out by reacting with a base such as sodium hydroxide or potassium hydroxide in a solvent such as an aqueous organic solvent or a polar organic solvent;
[0278] In the case of tBu, deprotection can be carried out by reacting with an acid such as trifluoroacetic acid (TFA) or hydrochloric acid in a solvent such as chloroform or ethyl acetate;
[0279] In the case of Bzl, deprotection can be carried out by reacting in a solvent such as methanol or DMF, or with a strong acid such as hydrogen fluoride, trifluoromethanesulfonic acid, HBr, or the like.
[0280] The acid that can be used for deprotection of the Boc group is not particularly limited, and inorganic acids such as hydrogen chloride, sulfuric acid, and nitric acid, carboxylic acids such as formic acid and trifluoroacetic acid (TFA), sulfonic acids such as methanesulfonic acid and p-toluenesulfonic acid, or mixtures thereof can be used. Examples of the mixture include hydrogen bromide / acetic acid, hydrogen chloride / dioxane, and hydrogen chloride / acetic acid.
[0281] The organic base that can be used for deprotection of the Fmoc group is not particularly limited, and examples thereof include secondary amines such as diethylamine, piperidine, and morpholine, and tertiary amines such as diisopropylethylamine, dimethylaminopyridine, 1,8-diazabicyclo[5.4.0]undecene-7 (DBU), 1,4-diazabicyclo[2.2.2]octane (DABCO), and 1,5-diazabicyclo[4.3.0]nonene-5 (DBN).
[0282] More preferably, the deprotection of the Fmoc group is carried out by treating with a non-nucleophilic organic base in a halogen solvent or an ether solvent. The deprotection is carried out in a solvent that does not affect the reaction.
[0283] Examples of the non-nucleophilic base include 1,8-diazabicyclo[5.4.0]undecene-7 (DBU), 1,4-diazabicyclo[2.2.2]octane (DABCO), and 1,5-diazabicyclo[4.3.0]nonene-5 (DBN). Preferred are DBU and DBN, and more preferred is DBU.
[0284] The deprotection of the pseudo-solid phase protecting group is preferably carried out by acid treatment. Examples of the acid used for deprotection include trifluoroacetic acid (TFA), hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, etc., among which TFA is preferred. Examples of the solvent used for deprotection include chloroform, dichloromethane, 1,2-dichloroethane, or a mixed solvent thereof. The concentration of the acid used for deprotection is, for example, 0.1 w / v% to 5 w / v%.
[0285] The deprotection of the pseudo-solid phase protecting group can also be carried out simultaneously with the deprotection of the protecting groups of other functional groups in the peptide. In this case, the conventional methods used in the art, especially in peptide synthesis, can be used, preferably the method of adding acid, etc. As the acid, trifluoroacetic acid (TFA), hydrochloric acid, sulfuric acid, methanesulfonic acid, toluenesulfonic acid, trifluoroethanol, hexafluoroisopropanol, etc. can be used. Among them, TFA is particularly good. Regarding the amount of acid used, it is appropriately set according to the type of acid used, and an amount suitable for removing the anchor group can be used. The amount of acid used is preferably 3 moles or more, more preferably 5 moles or more, preferably 100 moles or less, and more preferably 50 moles or less relative to 1 mole of peptide. While using these acids, trifluoromethanesulfonic acid, trimethylsilyl trifluoromethanesulfonate, BF3-etherate, etc. can also be added as a further strong acid source.
[0286] Those skilled in the art can appropriately select the above-mentioned deprotection conditions of the pseudo-solid phase protecting group according to the type of the protecting group used.
[0287] Other protecting groups can be appropriately deprotected according to the methods commonly used in the technical field or the methods for deprotecting protecting groups described in the present specification, depending on the types of the protecting groups.
[0288] When the "S-protected peptide" obtained by the above steps (1-A) and (1-B) is obtained under liquid phase conditions, it can be separated and purified by a conventional method in the art and provided to step (2). On the other hand, when the "S-protected peptide" is obtained under solid phase conditions, it can be cut out from the solid phase support by a conventional method and provided to step (2).
[0289] Above, step (1-A) and step (1-B) are described. As described above, in the present invention, the S-protected peptide of step (2) can be obtained by implementing step (1-A) and step (1-B), but the chronological relationship of implementing step (1-A) and step (1-B) is not limited to this order, and the order can be appropriately changed according to the embodiment. Therefore, it can be a case where step (1-B) is performed after step (1-A), a case where step (1-A) is performed after step (1-B), a case where a combination of them is performed, and a case where both steps are performed simultaneously, all of which are included in the scope of the present invention. Therefore, step (1-A) and step (1-B) together constitute step (1) for producing the "S-protected peptide" used in the subsequent step (2). That is, in other words, step (1) can be considered as a step for obtaining an "S-protected peptide" including the combined implementation of step (1-A) and step (1-B).
[0290] [About process (2)]
[0291] This step (2) is a step in which the "linear peptide having two or more SH groups as functional groups on the peptide, in which all SH groups are protected by forming temporary SS bonds and the protecting groups of all functional groups other than the SH groups are deprotected (S-protected peptide)" obtained by the above steps (1-A) and (1-B) is subjected to a folding step under redox conditions to obtain a cyclized peptide by re-forming SS bonds within the peptide molecule.
[0292] In this step, the temporary SS bond formed to protect the SH group in the folding step is temporarily cut (cleaved), and the SS bond is reformed to construct a stable (natural) higher-order structure, thereby obtaining the target cyclized peptide.
[0293] In the folding step of this step, under redox conditions, for the "S protected peptide", the SS bond exchange reaction is carried out in sequence by cleavage based on the reduction of its temporary SS bond and formation of the SS bond based on oxidation, and re-cleavage based on the reduction of the formed SS bond and reformation based on oxidation, and finally a cyclized peptide having a stable (natural type when the target cyclized peptide is a natural substance) higher-order structure is derived. In particular, in the case of a peptide having more than 4 SH groups, there is a combination of SS bond formation between more than two SH groups, but in this step, one or more SS bonds are formed between SH groups selected according to conditions suitable for the stable higher-order structure. In the previous method, for example, it is necessary to take measures in advance at the design stage of the linear peptide, such as protecting the SH group by different protecting groups according to the combination of SH groups to form SS bonds, but in the present invention, the target cyclized peptide can be obtained simply and effectively.
[0294] The "redox conditions" in the present invention refer to conditions under which the "S-protected peptide" is subjected to SS bond exchange reactions in sequence, which are cleavage of its temporary SS bond by reduction and formation of SS bond by oxidation, and then re-cleavage of the formed SS bond by reduction and reformation by oxidation, to finally derive a cyclized peptide having a stable (natural type when the target cyclized peptide is a natural substance) higher-order structure. Generally, the process is carried out in the coexistence of an oxidizing agent and a reducing agent, but as described later, only a reducing agent is required, and an oxidizing agent does not necessarily have to be added from the outside.
[0295] The combination of the oxidizing agent and the reducing agent used in this step can be a combination commonly used in the art, and examples thereof include a combination of a disulfide reagent / thiol reagent, for example, a combination of an oxidizing agent and a reducing agent such as cystine / cysteine, oxidized glutathione / reduced glutathione, cystamine / cysteamine, dithiodiethanol / β-mercaptoethanol, etc. Preferred forms of the "combination of an oxidizing agent and a reducing agent" include a combination of cystine / cysteine, and oxidized glutathione / reduced glutathione.
[0296] As described above, oxygen dissolved in the solvent acts as an oxidant, and the temporary SS bond itself present in the S-protected peptide also acts as an oxidant, so an embodiment in which an oxidant is not added from the outside and only a reducing agent is used is also included in the folding step under redox conditions in step (2). In the case in which an oxidant is not added from the outside and dissolved oxygen and the temporary SS bond itself present in the S-protected peptide act as an oxidant, examples of the reducing agent include cysteine, reduced glutathione, cysteamine, β-mercaptoethanol, etc. (preferably cysteine), but the reducing agent is not limited to these as long as it is a reducing agent commonly used in the technical field.
[0297] This step can be carried out in an appropriate solvent, preferably a polar solvent (eg, water, alcohol such as ethanol, etc.) or a mixed solvent thereof.
[0298] This step can be usually carried out at pH 6 or higher (14 or lower), preferably under alkaline conditions, for example, pH 7 or higher (14 or lower), more preferably pH 8 or higher (14 or lower), particularly preferably pH 8 or higher and pH 13 or lower.
[0299] This step can be carried out under the conditions for carrying out a folding step generally performed in the art.
[0300] The concentration of the "S protected peptide" when the folding step is performed is not particularly limited, and can be appropriately determined by those skilled in the art according to the type of the "S protected peptide", and can be performed, for example, in the usual concentration range of 0.1 mg / ml to 1 mg / ml for folding. As a result of the study, it was confirmed that in the present invention, the target cyclized peptide can be efficiently obtained in a higher concentration range based on the protection of the SH group by forming a temporary SS bond, and this step can be performed in the range of 1 mg / ml or more and 50 mg / ml, or 1 mg / ml or more and 25 mg / ml, or 1 mg / ml or more and 15 mg / ml.
[0301] Regarding the method for implementing the folding step under other redox conditions, a person skilled in the art can select according to a method known in the art based on a suitable substrate peptide, and can also refer to, for example, "Fundamentals and Experiments of Peptide Synthesis, published by Maruzen Co., Ltd. (1985)".
[0302] The embodiments serving as the basis of the present invention have been described above, and preferred embodiments will be described below in sequence.
[0303] Step (1): [Regarding step (1-A) and step (1-B)].
[0304] Implementation Method 1
[0305] When carrying out the present invention, in step (1-B), all SH groups can be protected by forming temporary SS bonds within the peptide molecule and / or between peptide molecules (temporary SSization).
[0306] In this embodiment, any set of SH groups of a linear peptide having two or more SH groups as functional groups on the peptide forms temporary SS bonds within the peptide molecule and / or between peptide molecules, thereby protecting the SH groups and obtaining a mixture of peptides cross-linked or linked by temporary SS bonds (temporary SS-modified peptide mixture). Here, a mixture of peptides having various structures linked by temporary SS bonds can be obtained, but there is no need for special purification or screening of specific compounds, and the entire mixture can be used in the next step, which is useful.
[0307] The temporary SS-reaction is carried out by appropriately combining the protective group of the SH group used in the target peptide and the method of forming the temporary SS bond.
[0308] Implementation Method 1-1
[0309] In this embodiment, more specifically,
[0310] In step (1-B), the fully protected peptide is subjected to temporary SS-treatment to obtain a temporary SS-treated peptide mixture, and then,
[0311] In step (1-A), the protective groups of all functional groups of the temporarily SS-modified peptide mixture except the SH group protected by forming a temporary SS bond are deprotected, thereby obtaining an S-protected peptide.
[0312] In the present embodiment, preferred protecting groups for the SH group in the fully protected peptide include protecting groups other than S-type protecting groups (described later), such as trityl (Trt group), acetylaminomethyl (Acm group), benzyl (Bzl group), 4-methylbenzyl (4-MeBzl group), and 4-methoxybenzyl (MBzl group).
[0313] In the present embodiment, temporary SS conversion is performed by, for example, iodine treatment, thallium (III) trifluoroacetate treatment (Tl(OCOCF3)3 treatment), etc., preferably, iodine treatment.
[0314] Each treatment such as the above-mentioned iodine treatment can be carried out under the conditions commonly used in the art. For example, in the case of iodine treatment, it can be carried out by treating the fully protected peptide with iodine in a solvent such as chloroform, acetic acid, methanol and other alcohols, hexafluoroisopropanol, or in their aqueous or mixed solvents. The amount of iodine used is, for example, 0.3 to 8 equivalents, preferably 0.5 to 6 equivalents, relative to the peptide structural unit (1 mol) having an SH group. In another embodiment, the amount of iodine used is, for example, 1 to 6 equivalents, preferably 1 to 3 equivalents, relative to the peptide structural unit (1 mol) having an SH group. When the protecting group of the SH group is an acetylaminomethyl group (Acm group), the amount used is 1 to 10 equivalents, preferably 1 to 5 equivalents. The temperature during the treatment is not particularly limited, and can be appropriately selected according to the reaction in the temperature range of cooling to heating. For example, it can be carried out at room temperature (normal temperature). In the temporary SS conversion, even when the treatment is performed with other oxidizing agents (thallium (III) trifluoroacetate, etc.), the same equivalent relationship and temperature conditions can be adopted.
[0315] The thallium (III) trifluoroacetate treatment is a method in which thallium (III) trifluoroacetate (Tl(OCOCF3)3) is used as an oxidizing agent, and can be performed, for example, by treating a fully protected peptide with the oxidizing agent in trifluoroacetic acid (TFA).
[0316] In this embodiment, the protecting groups of functional groups other than the SH group and the conditions for their deprotection can be implemented as described above, and the deprotection is preferably carried out by treating with trifluoroacetic acid (TFA).
[0317] Implementation 1-2
[0318] In this embodiment, more specifically,
[0319] In step (1-A), the protecting groups of all functional groups other than the SH group of the fully protected peptide are deprotected, and subsequently or simultaneously,
[0320] In step (1-B), the peptide is subjected to temporary SS-treatment to obtain a temporary SS-treated peptide mixture, thereby obtaining an S-protected peptide.
[0321] In the present embodiment, as the preferred protecting group for the SH group in the fully protected peptide, there can be mentioned protecting groups other than S-type protecting groups, for example, acetylaminomethyl (Acm group), tert-butyl (t-Bu group), trityl (Trt group), benzyl (Bzl group), 4-methylbenzyl (4-MeBzl group), 4-methoxybenzyl (MBzl group).
[0322] In this embodiment, temporary SSization is performed by, for example, iodine treatment, DMSO / TFA (dimethyl sulfoxide / trifluoroacetic acid) treatment, thallium (III) trifluoroacetate treatment (Tl(OCOCF3)3 treatment), etc., preferably, iodine treatment.
[0323] In this embodiment, the deprotection of step (1-A) and the temporary SS-ization of step (1-B) can also be performed simultaneously, for example, by using DMSO / TFA treatment. Specifically, 10% DMSO / TFA (DMSO:TFA=1:10) can be used. In this treatment, the same equivalent relationship and temperature conditions as those in the above-mentioned iodine treatment can also be used.
[0324] The details of the iodine treatment and the thallium (III) trifluoroacetate treatment can be found above.
[0325] The protecting groups of functional groups other than the SH group and the conditions for their deprotection can be carried out with reference to the above description. The deprotection is preferably carried out by treating with trifluoroacetic acid.
[0326] Implementation 1-3
[0327] In this embodiment, more specifically,
[0328] a) 1) In step (1-A), all protective groups of the fully protected peptide except the SH group are deprotected, and then
[0329] 2) Remove the SH protecting group, and then
[0330] 3) in step (1-B), subjecting to temporary SS-treatment to obtain a temporary SS-treated peptide mixture;
[0331] or
[0332] b) 1) deprotecting the SH group of the fully protected peptide, and then
[0333] 2) In step (1-B), the peptide mixture is temporarily SS-treated to obtain a temporarily SS-treated peptide mixture, and then
[0334] 3) In step (1-A), the protective groups of all functional groups of the temporarily SS-modified peptide mixture except the SH group protected by forming a temporary SS bond are deprotected to obtain an S-protected peptide.
[0335] In this embodiment, preferred protecting groups for the SH group in the fully protected peptide include protecting groups other than S-type protecting groups, such as phenylacetylaminomethyl (Phacm group), 4-methoxybenzyl (MBzl group), and monomethoxytrityl (MMTrt group).
[0336] The above-mentioned protecting groups can be appropriately deprotected according to the methods commonly used in the art or the deprotection methods of the protecting groups described in this specification, depending on their types. In the present embodiment, when the protecting group of the SH group is a phenylacetylaminomethyl group (Phacm group), its removal is preferably carried out by treatment with an aqueous solution in the presence of penicillin amidohydrolase (PGA). When the protecting group of the SH group is a 4-methoxybenzyl group (MBzl group), its removal is preferably carried out by treatment with DDQ (dichlorodicyanobenzoquinone). When the protecting group of the SH group is a monomethoxytrityl group (MMTrt group), its removal is preferably carried out by treatment with a weak acid (e.g., 1% TFA).
[0337] In this embodiment, temporary SSization is carried out by, for example, iodine treatment, Npys-OMe treatment (3-nitro-2-pyridine methyl sulfonate treatment), thallium (III) trifluoroacetate treatment (Tl(OCOCF3)3 treatment), etc., preferably by iodine treatment or Npys-OMe treatment, and more preferably by iodine treatment.
[0338] Npys-OMe treatment (3-nitro-2-pyridinesulfenic acid methyl ester treatment) is a method using Npys-OMe as an oxidant, and can be carried out by treating the fully protected peptide with the oxidant in chloroform, DMF, acetonitrile, or a mixed solvent thereof. In this treatment, the same equivalent relationship and temperature conditions as those in the above-mentioned iodine treatment can also be used.
[0339] The details of the iodine treatment and the thallium (III) trifluoroacetate treatment can be found above.
[0340] The protecting groups of functional groups other than the SH group and the conditions for their deprotection can be carried out with reference to the above description. The deprotection is preferably carried out by treating with trifluoroacetic acid (TFA).
[0341] Implementation Method 2
[0342] When carrying out the present invention, in step (1-B), all SH groups are protected by forming temporary SS bonds with S-type protecting groups.
[0343] Implementation Method 2-1
[0344] In this embodiment, more specifically,
[0345] (1)(i) In step (1-B), the protecting group of the SH group of a linear peptide having two or more SH groups protected by protecting groups as functional groups on the peptide, wherein the N-terminal amino group may be protected and the C-terminal carboxyl group and all other functional groups on the peptide are protected, is re-protected with an S-type protecting group, or
[0346] (ii) pre-protected with an S-type protecting group, thereby obtaining a peptide in which all SH groups are protected by forming temporary SS bonds with the S-type protecting group;
[0347] (2) In step (1-A), the protective groups of all functional groups of the peptide except the SH group temporarily protected by the SS bond are deprotected to obtain an S-protected peptide.
[0348] The formation of a temporary SS bond with an S-type protecting group can be carried out by treating, for example, a reagent for introducing an S-type protecting group used in the art such as 3-nitro-2-pyridinesulfinyl (Npys group), tert-butylthiol (S-tBu group) or ethylthiol (S-Et group) under commonly used conditions. For example, when NpysCl is used as a reagent for introducing a 3-nitro-2-pyridinesulfinyl (Npys group), the reaction can be carried out in chloroform, DMF, acetonitrile, or a mixed solvent thereof. The amount of the reagent used to introduce an S-type protecting group is 1 to 6 equivalents, preferably 1 to 3 equivalents, relative to a peptide structural unit (1 mol) having an SH group (or a protected SH group). In addition, the temperature during the treatment is not particularly limited and can be appropriately selected according to the reaction in the temperature range of cooling to heating. For example, it can be carried out at room temperature (normal temperature).
[0349] "Reprotection of the protective group of the SH group of the peptide with an S-type protective group" refers to the following aspect: a peptide whose SH group is protected by a protective group other than an S-type protective group is reprotected by a reagent for introducing an S-type protective group, so that all SH groups form temporary SS bonds with the S-type protective group. In this case, the S-type protective group is preferably a 3-nitro-2-pyridinesulfinyl group (Npys group).
[0350] On the other hand, "preliminarily protected with an S-type protecting group" means that a peptide raw material containing an SH group as a functional group (cysteine residue, homocysteine residue, 3-mercaptopropionyl group, etc.) is preliminarily protected with an S-type protecting group (e.g., tert-butylmercapto (S-tBu group), ethylmercapto (S-Et group), 3-nitro-2-pyridinesulfinyl (Npys group), etc.). In this case, the S-type protecting group is preferably tert-butylmercapto (S-tBu group).
[0351] As the protecting group for the SH group in the case of “reprotecting the protecting group for the SH group of the peptide with an S-type protecting group”, a protecting group other than an S-type protecting group can be used, and for example, a trityl group (Trt group) can be used.
[0352] The protecting groups of the functional groups other than the SH group, the conditions for their deprotection, etc. can be carried out with reference to the above description, and the deprotection is preferably carried out by treating with trifluoroacetic acid (TFA).
[0353] In the above, the embodiments of steps (1-A) and (1-B) in step (1) of the present invention are described. However, since the SH group of a peptide having an SH group as a functional group on the peptide is deprotected while the SH group is protected, it is possible to solve the problem that "the residues of various protecting groups after deprotection of the SH group are alkylated, the yield is reduced, and the yield of the target peptide in the cyclization reaction is inevitably reduced due to the generation of impurities as by-products."
[0354] Furthermore, by forming a temporary SS bond, the SH group is protected, thereby improving the folding efficiency of the step (2).
[0355] [About process (2)].
[0356] Implementation Method 1
[0357] In this embodiment, the folding step of step (2) is carried out in an aqueous solution at pH 6 or higher, preferably under alkaline conditions, for example, at pH 7 or higher (14 or lower), more preferably at pH 8 or higher (14 or lower), and particularly preferably at pH 8 or higher and pH 13 or lower.
[0358] Implementation Method 2
[0359] In the present embodiment, the concentration of the "S-protected peptide" in the system in the folding step of step (2) is carried out within a concentration range commonly used for folding, for example, 0.1 mg / ml to 1 mg / ml.
[0360] Implementation Method 2-1
[0361] In this embodiment, the concentration of the "S protective peptide" in the system in the folding step of step (2) is in a concentration range of 1 mg / ml or more, for example, 1 mg / ml to 50 mg / ml, or 1 mg / ml to 25 mg / ml, or 1 mg / ml to 15 mg / ml.
[0362] The above is an explanation of the embodiment of step (2) of the present invention, which has a great advantage in that a cyclization reaction can be performed at a higher concentration than the usual folding conditions. In the folding step of the present invention, in a few cases, the reagent used as a redox agent forms an SS bond with the peptide and generates additional impurities as a by-product. However, in the usual method, the impurities generated as by-products are multimers with a large molecular weight, and there are many types of them. In the method of the present invention, even if it is assumed that additional impurities are generated as by-products, they are not multimers with a large molecular weight, and they are impurities of a single type, so the subsequent purification load can be greatly reduced. Step (2) of the present invention also has such a great advantage.
[0363] Furthermore, preferred embodiments of the present invention will be described based on an overall viewpoint.
[0364] When the present invention is implemented, the number of SH groups possessed by the S-protected peptide is 2 or more. In a preferred embodiment, the number of SH groups possessed by the S-protected peptide is 2.
[0365] In another preferred embodiment, the number of SH groups possessed by the S-protected peptide is 4 or more, preferably an even number.
[0366] In the practice of the present invention, the number of residues of structural units such as amino acids and amino acid analogs constituting the S-protected peptide is not particularly limited, but is usually 4 to 100, preferably 6 to 80, and more preferably 8 to 60.
[0367] When implementing the present invention, the type of cyclized peptide used as the object is not particularly limited, and for example, it can be a drug. In addition, it can be a natural substance or a non-natural substance. As such cyclized peptides, for example, somatostatin, octreotide, atosiban, linaclotide, plecanatide, ziconotide, insulin detemir, insulin glulisine, etc. can be cited, but are not limited thereto.
[0368] When carrying out the present invention, in the folding step under redox conditions of the present invention, it is preferred to target a substance that can be induced (derived) into a cyclized peptide having a stable (natural type when the target cyclized peptide is a natural substance) higher order structure.
[0369] Example
[0370] Below, based on embodiment, the present invention is described in more detail, but these embodiments do not cause any limitation to the scope of the present invention. In addition, as long as not specifically mentioned, the reagent and device, material used in the present invention can be obtained by commercial means. In addition, in this specification, when amino acid etc. are represented by abbreviated symbols, each representation is based on the abbreviated symbols defined by IUPAC-IUB Biochemical Nomenclature Committee (IUPAC-IUB Commission on Biochemical Nomenclature) or the customary abbreviated symbols in this area. In addition, when there is a record of equivalent about the reagent used, it refers to the equivalent based on the concatemer of the peptide as raw material (for example, the concatenated complete protection body of peptide A).
[0371] Preparation Example 1: Tandem fully protected peptide A
[0372] Using Fmoc-Tyr(tBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gly-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, and Fmoc-Glu(OtBu)-OH as raw materials and 3,4,5-tris(2',3'-dihydrophytyloxy)benzyl alcohol (referred to as HO-Bzl(3,4,5-OPhy)) as a pseudo-solid phase protecting group, a tandem fully protected form of peptide A having the following sequence was synthesized according to conventional methods (see International Publication No. 2012 / 029794; Angew Chem. Int. Ed. 2017.27, (56), 7803). It should be noted that in this specification, the term "fully protected peptide" refers to a concept that includes the case where the N-terminal amino group may be protected and is unprotected, and thus a peptide with no N-terminal protection is also referred to as a "tandem fully protected peptide". The Fmoc group at the N-terminus of the following peptides was cleaved with a base according to a conventional method.
[0373] Tandem fully protected peptide A
[0374] H-Cys(Trt)-Cys(Trt)-Glu(OtBu)-Tyr(tBu)-Cys(Trt)-Cys(Trt)-Asn(Trt)-Pro-Ala-Cys(Trt)-Thr(tBu)-Gly-Cys(Trt)-Tyr(tBu)-OBzl(3,4,5-OPhy).
[0375] Preparation Example 2: Tandem fully protected peptide B
[0376] Using 3-mercapto (Trt) propionic acid, Fmoc-O-ethyl-D-Tyr-OH, Fmoc-Ile-OH, Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Pro-OH, Fmoc-Orn(Boc)-OH, and Fmoc-Gly-OH as raw materials, and using 3,4,5-tris(2',3'-dihydrophytyloxy)benzyl alcohol (denoted as HO-Bzl(3,4,5-OPhy)) as a pseudo-solid phase protecting group, a tandem fully protected form of peptide B having the following sequence was synthesized according to conventional methods (see International Publication No. 2012 / 029794; Angew Chem. Int. Ed. 2017.27, (56), 7803).
[0377] Tandem fully protected peptide B:
[0378] 3-Mercapto(Trt)propionyl-O-ethyl-D-Tyr-Ile-Thr(tBu)-Asn(Trt)-Cys(Trt)-Pro-Orn(Boc)-Gly-OBzl(3,4,5-OPhy).
[0379] Preparation Example 3: Tandem fully protected peptide A'
[0380] Using Fmoc-Tyr(tBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gly-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, and Fmoc-Glu(OtBu)-OH as raw materials, and using Alko-PEG resin (Wang-PEG resin manufactured by Watanabe Chemical Industry Co., Ltd.) as a solid phase protecting group, a fully protected peptide A' having the following sequence was synthesized according to a conventional method. It should be noted that in this specification, the "fully protected peptide" is a concept that includes the case where the N-terminal amino group may be protected, and therefore a peptide without protection at the N-terminal end is also referred to as a "tandem fully protected peptide". It should be noted that the Fmoc group at the N-terminus of the following peptide was cleaved with a base according to a conventional method.
[0381] Tandem fully protected peptide A':
[0382] H-Cys(Trt)-Cys(Trt)-Glu(OtBu)-Tyr(tBu)-Cys(Trt)-Cys(Trt)-Asn(Trt)-Pro-Ala-Cys(Trt)-Thr(tBu)-Gly-Cys(Trt)-Tyr(tBu)-Alko-PEG resin.
[0383] Example 1: Temporary SS-S pathway based on iodine oxidation (folding concentration: 1 mg / ml)
[0384] 100 mg of the tandem fully protected form of peptide A was dissolved in 3.4 ml of chloroform and 0.6 ml of MeOH (methanol), and 3 equivalents of iodine (17.2 mg) were added. After the reaction, the solution was separated twice with an aqueous solution obtained by dissolving 39.7 mg of ascorbic acid in 3.4 ml of water, and then washed twice with a 20% NaCl (sodium chloride) aqueous solution. The obtained organic layer was concentrated and dried using an evaporator. The solid was added to a mixed solution of 0.975 ml of TFA (trifluoroacetic acid), 0.025 ml of water, and 2 equivalents of p-cresol (24.4 mg) for deprotection. 5 ml of IPE (isopropyl ether) was added and the precipitate was filtered and dried to obtain 67.7 mg of a deprotected / temporarily SS-ylated peptide mixture. To a mixed solution of 1 ml of water, 1 ml of EtOH (ethanol), 1.0 mg of cystine, and 0.3 mg of cysteine, 2.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained above was added, and 3 μl of aqueous ammonia was added to adjust the pH to 9.8. After 6 hours, when the reaction solution was analyzed by HPLC, it was confirmed that 0.6 mg of cyclized peptide A having the following structure was generated with a purity of 82% (the yield was 52% relative to the fully protected concatemer of peptide A).
[0385] <Elution conditions>
[0386] Elution time: 4.05 minutes
[0387] Instrument used: Waters ACQUITY UPLC
[0388] Column: BEH Shield RP18 1.7μm 2.1×100mm
[0389] Temperature: 40℃
[0390] Flow rate: 0.30ml / min
[0391] Mobile phase: Liquid A, 0.05% TFA / H2O; Liquid B, 0.05% TFA / MeCN(20)THF(80)
[0392] Time program (Liquid A ratio)
[0393] 0.00-0.05 minutes 99%
[0394] 0.05-13.00 minutes 99-1%.
[0395] Cyclic peptide A:
[0396] H-Cys 1 -Cys 2 -Glu 3 -Tyr 4 -Cys 5 -Cys6 -Asn 7 -Pro 8 -Ala 9 -Cys 10 -Thr 11 -Gly 12 -Cys 13 -Tyr 14 -OH
[0397] (Here, in Cys 1 With Cys 6 Between, Cys 2 With Cys 10 Between, Cys 5 With Cys 13 SS bond is formed between them) (SEQ ID NO: 1)
[0398] m / z[M+H] + 1526.3.
[0399] Example 2: Temporary SS-S pathway based on iodine oxidation (folding concentration: 4 mg / ml)
[0400] To a mixed solution of 1 ml of water, 1 ml of EtOH, 1.0 mg of cystine, and 0.3 mg of cysteine, 8.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained in Example 1 was added, and the pH was adjusted to 9.3 by adding 6 μl of aqueous ammonia. After 6 hours, the reaction solution was analyzed by HPLC, and it was confirmed that 2.2 mg of cyclized peptide A was generated with a purity of 81% (the yield was 54% relative to the fully protected concatemer of peptide A).
[0401] Example 3: Temporary SS-S pathway based on iodine oxidation (folding concentration: 10 mg / ml)
[0402] To a mixed solution of 1 ml of water, 1 ml of EtOH, 1.0 mg of cystine, and 0.3 mg of cysteine, 20.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained in Example 1 was added, and 6 μl of aqueous ammonia was added to adjust the pH to 9.8. After 6 hours, the reaction solution was analyzed by HPLC, and it was confirmed that 4.9 mg of cyclized peptide A was generated with a purity of 72% (48% yield relative to the fully protected concatemer of peptide A).
[0403] Example 4: Temporary SS-forming pathway based on 10% DMSO oxidation / TFA deprotection (folding concentration: 1 mg / ml) 50 mg of the tandem fully protected form of peptide A was added to a mixed solution of 1.0 ml TFA and 0.1 ml DMSO (dimethyl sulfoxide) and deprotected at room temperature for 5 hours. 5 ml IPE was added and the precipitate was filtered and dried to obtain 19.4 mg of a deprotected / temporary SS-forming peptide mixture. 2.0 mg of the deprotected / temporary SS-forming peptide mixture obtained above was added to a mixed solution of 1.0 ml water, 1.0 ml EtOH, 1.0 mg cystine, and 0.3 mg cysteine, 3 μl of ammonia water was added to adjust the pH to 9.5 and stirred at room temperature. After 5 hours, when the reaction solution was analyzed by HPLC, it was confirmed that 0.9 mg of cyclized peptide A was generated with a purity of 81% (yield 48% relative to the tandem fully protected form of peptide A).
[0404] Example 5: Temporary SS bond formation pathway of Npys-based S-type protecting groups (folding concentration: 1 mg / ml) 100 mg of the tandem fully protected form of peptide A was dissolved in 3.4 ml of chloroform and 0.6 ml of MeOH, and 6 equivalents of Npys-Cl (3-nitro-2-pyridinesulfenyl chloride) and 25.8 mg were added. After the reaction, the solution was separated twice with an aqueous solution obtained by dissolving 39.7 mg of ascorbic acid in 3.4 ml of water, and then washed twice with a 20% NaCl aqueous solution. The obtained organic layer was concentrated and dried with an evaporator. The solid was added to a mixed solution of 1.95 ml of TFA, 0.05 ml of water, and 10 equivalents of p-cresol and 24.4 mg, and deprotected. 10 ml of IPE was added and the precipitate was filtered and dried to obtain 84.7 mg of deprotected / S-type protecting group Npys-based protected peptide. To a mixed solution of 1 ml of water, 1 ml of EtOH, 1.0 mg of cystine, and 0.3 mg of cysteine, 2.0 mg of the deprotected / S-type protecting group Npys-protected peptide obtained above was added, and 3 μl of aqueous ammonia was added to adjust the pH to 9.8. After 2 hours, the reaction solution was analyzed by HPLC, and it was confirmed that 0.8 mg of cyclized peptide A was generated with a purity of 73% (the yield was 56% relative to the fully protected concatemer of peptide A).
[0405] Example 6: Temporary SS-S pathway based on iodine oxidation (folding concentration: 10 mg / ml)
[0406] 137 mg of the tandem fully protected form of peptide A' was dissolved in 3.4 ml of chloroform and 0.6 ml of MeOH, and 3 equivalents of iodine, 17.2 mg, and 0.068 mmol were added, and stirred at room temperature for 2 hours. After the reaction, the solution was separated twice with an aqueous solution obtained by dissolving 39.7 mg of ascorbic acid in 3.4 ml of water, and then washed twice with 3.4 ml of a 20% NaCl aqueous solution. The obtained organic layer was concentrated and dried using an evaporator. The solid was added to a mixed solution of 1.95 ml of TFA, 0.05 ml of water, and 10 equivalents of p-cresol, 24.4 mg, and deprotected at room temperature for 5 hours. After washing the resin with 2 ml of TFA by filtration, 10 ml of IPE was added to the filtrate, the precipitate was filtered, and dried to obtain 34.5 mg of a deprotected / temporarily SS-ylated peptide mixture. To a mixed solution of 1.7 ml of water, 1.7 ml of EtOH, 1.7 mg of cystine, and 0.6 mg of cysteine, 34.5 mg of the deprotected / temporarily SS-ylated peptide mixture obtained above was added, 60 μl of ammonia water was added to adjust the pH to 9.2, and stirred at room temperature. After 1 hour, when the reaction solution was analyzed by HPLC, it was confirmed that 17 mg of cyclized peptide A was generated with a purity of 68% (49% yield relative to the tandem fully protected form of peptide A').
[0407] Example 7: Temporary SS-S pathway based on iodine oxidation (folding concentration: 1 mg / ml)
[0408] 1.0 g of the tandem fully protected form of peptide B was dissolved in 16.8 ml CPME (cyclopentyl methyl ether) and 4.2 ml MeOH, and 1 equivalent of iodine, 48.4 mg, was added. After the reaction, the solution was separated twice with an aqueous solution obtained by dissolving 671 mg of ascorbic acid in 21 ml of water, and then washed twice with a 20% NaCl aqueous solution. The obtained organic layer was concentrated and dried with an evaporator to obtain 894 mg of solid. 300 mg of the solid was added to a mixed solution of 5.85 ml TFA, 0.25 ml water, 10 equivalents of p-cresol, and 150 mg, and deprotected. 24 ml of IPE was added and the precipitate was filtered and dried to obtain a deprotected / temporarily SS-type peptide mixture. To a mixed solution of 1 ml of water, 1 ml of EtOH, 1.0 mg of cystine, and 0.3 mg of cysteine, 2.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained above was added, and 3 μl of aqueous ammonia was added to adjust the pH to 9.8. After 6 hours, the reaction solution was analyzed by HPLC, confirming that cyclized peptide B was generated with a purity of 85%.
[0409] <Elution conditions>
[0410] Elution time: 4.90 minutes
[0411] Instrument used: Waters ACQUITY UPLC
[0412] Column: BEH Shield RP18 1.7μm 2.1×100mm
[0413] Temperature: 40℃
[0414] Flow rate: 0.30ml / min
[0415] Mobile phase: Liquid A, 0.05% TFA / H2O; Liquid B, 0.05% TFA / MeCN(20)THF(80)
[0416] Time program (Liquid A ratio)
[0417] 0.00-0.05 minutes 99%
[0418] 0.05-13.00 minutes 99-1%.
[0419] Cyclic peptide B:
[0420] 3-Mercaptopropionyl-O-ethyl-D-Tyr-Ile-Thr-Asn-Cys-Pro-Orn-Gly-NH2
[0421] (Here, an SS bond is formed between 3-mercaptopropionyl and Cys)
[0422] m / z[M+H] + 994.4.
[0423] Example 8: Temporary SS-S pathway based on iodine oxidation (folding concentration: 6.5 mg / ml)
[0424] To a mixed solution of 1 ml of water, 1 ml of EtOH, 1.0 mg of cystine, and 0.3 mg of cysteine, 13.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained in Example 7 was added, and 3 μl of aqueous ammonia was added to adjust the pH to 8.9. After 1 hour, the reaction solution was analyzed by HPLC, confirming that cyclized peptide B was generated with a purity of 77%.
[0425] Comparative Example 1: Conventional route (folded concentration: 1 mg / ml)
[0426] 6.00 g of the tandem fully protected form of peptide A was added to a mixed solution of 114 ml TFA, 3 ml water, 3 ml TIPS (triisopropylsilane), 10 equivalents of 3-mercaptopropionic acid, and 1.44 g, and deprotected at 10°C for 5 hours. 600 ml IPE was added and the precipitate was filtered and dried to obtain the peptide A tandem form. 2.0 mg of the peptide A tandem form obtained above was added to a mixed solution of 1.0 ml water, 1.0 ml EtOH, 1.0 mg cystine, and 0.3 mg cysteine, 3 μl of ammonia water was added to adjust the pH to 10.0 and stirred at room temperature. After 1 hour, when the reaction solution was analyzed by HPLC, it was confirmed that 0.6 mg of cyclized peptide A was generated with a purity of 72% (with a yield of 39% relative to the tandem fully protected form of peptide A).
[0427] Comparative Example 2: Conventional route (folded concentration: 10 mg / ml)
[0428] To a mixed solution of 1.0 ml of water, 1.0 ml of EtOH, 1.0 mg of cystine, and 0.3 mg of cysteine, 20 mg of the peptide A concatemer obtained in Comparative Example 1 was added, and 3 μl of ammonia water was added to adjust the pH to 9.1, and stirred at room temperature. After 1 hour, when the reaction solution was analyzed by HPLC, it was confirmed that 0.4 mg of cyclized peptide A was generated with a purity of 8% (with respect to the concatemer fully protected form of peptide A, the yield was 2%).
[0429] Comparative Example 3: Conventional route (folded concentration: 1 mg / ml)
[0430] 1.0 g of peptide B tandem fully protected body was added to a mixed solution of 7.60 ml TFA, 0.20 ml water, 0.20 ml triisopropylsilane, 10 equivalents of 3-mercaptopropionic acid, 405 mg, and 10 equivalents of p-cresol, 412 mg, for deprotection. 40 ml IPE was added and the precipitate was filtered and dried to obtain peptide B tandem body. 2.0 mg of peptide B tandem body obtained above was added to a mixed solution of 1 ml water, 1 ml EtOH, 1.0 mg cystine, and 0.3 mg cysteine, and 3 μl of ammonia water was added to adjust the pH to 9.7. After 6 hours, when the reaction solution was analyzed by HPLC, it was confirmed that cyclized peptide B was generated with a purity of 61%.
[0431] Comparative Example 4: Conventional route (folded concentration: 6.5 mg / ml)
[0432] To a mixed solution of 1 ml of water, 1 ml of EtOH, 0.3 mg of cystine, and 0.1 mg of cysteine was added 13.0 mg of the peptide B concatemer obtained in the above-mentioned Comparative Example 3, and 3 μl of ammonia water was added to adjust the pH to 9.6. After 6 hours, when the reaction solution was analyzed by HPLC, it was confirmed that cyclized peptide B was generated with a purity of 17%.
[0433] Comparative Example 5: Conventional route (folded concentration: 10 mg / ml)
[0434] 67.8 mg of peptide A's tandem fully protected body was added to a mixed solution of 1.9 ml TFA, 50 μl water, 50 μl triisopropylsilane, 100 equivalents of 3-mercaptopropionic acid, and 240 mg, and deprotected at room temperature for 5 hours. After filtering and washing the resin with 2 ml TFA, 20 ml IPE was added to the filtrate, the precipitate was filtered, and dried to obtain 15.6 mg of peptide A tandem body. 10.0 mg of peptide A tandem body obtained above was added to a mixed solution of 0.5 ml water, 0.5 ml EtOH, 5.0 mg cystine, and 0.2 mg cysteine, 3 μl ammonia water was added to adjust the pH to 9.5 and stirred at room temperature. After 1 hour, when the reaction solution was analyzed by HPLC, it was confirmed that 2.4 mg of cyclized peptide A was generated with a purity of 23% (with a yield of 21% relative to the tandem fully protected body of peptide A').
[0435] Example 9: Folding based on reducing agent only (folding concentration: 2 mg / ml)
[0436] To a mixed solution of 1 ml of water, 1 ml of EtOH and 0.3 mg of cysteine, 4.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained in Example 1 was added, and 3 μl of aqueous ammonia was added to adjust the pH to 9.9. After 6 hours, the reaction solution was analyzed by HPLC, and it was confirmed that 3.1 mg of cyclized peptide A was generated with a purity of 77.8% (the yield was 77% relative to the fully protected concatemer of peptide A).
[0437] Example 10: Folding based on different oxidants / reducing agents (folding concentration: 1 mg / ml)
[0438] To a mixed solution of 1 ml of water, 1 ml of EtOH, 6.0 mg of oxidized glutathione, and 2.0 mg of reduced glutathione, 2.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained in Example 1 was added, and 3 μl of aqueous ammonia was added to adjust the pH to 9.3. After 1 hour, the reaction solution was analyzed by HPLC, and it was confirmed that 0.9 mg of cyclized peptide A was generated with a purity of 65.0% (the yield was 56% relative to the fully protected concatemer of peptide A).
[0439] Preparation Example 4: Tandem fully protected peptide A
[0440] Using Fmoc-Tyr(tBu)-OH, Fmoc-Cys(S-tBu)-OH, Fmoc-Gly-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, and Fmoc-Glu(OtBu)-OH as raw materials and Alko-PEG resin (manufactured by Watanabe Chemical Industries, Ltd., Wang-PEG resin) as a solid phase protecting group, a tandem fully protected form of peptide A" having the following sequence was synthesized according to a conventional method. It should be noted that the Fmoc group at the N-terminus of the following peptide was cleaved with a base according to a conventional method.
[0441] Tandem fully protected peptide A:
[0442] H-Cys(S-tBu)-Cys(S-tBu)-Glu(OtBu)-Tyr(tBu)-Cys(S-tBu)-Cys(S-tBu)-Asn(Trt)-Pro-Ala-Cys(S-tBu)-Thr(tBu)-Gly-Cys(S-tBu)-Tyr(tBu)-Alko-PEG resin.
[0443] Example 11: Temporary SS bond formation pathway based on S-type protecting groups (folding concentration: 1 mg / ml)
[0444] 160 mg of the fully protected tandem peptide A" was added to a mixed solution of 2.59 ml TFA, 66.5 μl water, 10 equivalents of p-cresol, and 32.4 mg for deprotection. 30 ml IPE was added and the precipitate was filtered and dried to obtain 48.6 mg of the following peptide A" tandem.
[0445] Peptide A" concatemer:
[0446] H-Cys(S-tBu)-Cys(S-tBu)-Glu-Tyr-Cys(S-tBu)-Cys(S-tBu)-Asn-Pro-Ala-Cys(S-tBu)-Thr-Gly-Cys(S-tBu)-Tyr-OH.
[0447] To a mixed solution of 1 ml of water, 1 ml of EtOH, and 10 mg of cysteine, 2.0 mg of the concatemer of peptide A" obtained above was added, and 2 μl of aqueous ammonia was added to adjust the pH to 9.3. After 16 hours, the reaction solution was analyzed by HPLC, and it was confirmed that 1.0 mg of cyclized peptide A was generated with a purity of 52.2% (the yield relative to the concatemer of peptide A" was 51%).
[0448] <Elution conditions>
[0449] Elution time: 4.10 minutes
[0450] Instrument used: Waters ACQUITY UPLC
[0451] Column: BEH Shield RP18 1.7μm 2.1×100mm
[0452] Temperature: 40℃
[0453] Flow rate: 0.30ml / min
[0454] Mobile phase: Liquid A, 0.05% TFA / H2O; Liquid B, 0.05% TFA / MeCN(20)THF(80)
[0455] Time program (Liquid A ratio)
[0456] 0.00-0.05 minutes 99%
[0457] 0.05-13.00 minutes 99-1%.
[0458] Example 12: Temporary SS-ylation route based on deprotection of SH protecting group / iodine oxidation (folding concentration: 1 mg / ml) 160 mg of the tandem fully protected form of peptide A" was added to a mixed solution of 2 ml of water, 60 equivalents of DTT (dithiothreitol), 278 mg, and 3 μl of aqueous ammonia to carry out selective deprotection of the S-tBu group. The resin was washed by filtration to obtain the selectively deprotected form. The selectively deprotected form was dissolved in a mixed solution of 1.7 ml of chloroform and 0.3 ml of methanol, and 12 equivalents of iodine, 91.4 mg, were added. After the reaction, the resin was washed by filtration. The solid was added to a mixed solution of 2.59 ml of TFA, 66.5 ml of water, and 32.4 mg of p-cresol for deprotection. 20 ml of IPE was added and the precipitate was filtered and dried to obtain 45.6 mg of a deprotected / temporary SS-ylation peptide mixture. Add 1 ml of water, 1 ml To a mixed solution of EtOH, 0.3 mg of cystine, and 0.3 mg of cysteine, 2.0 mg of the deprotected / temporarily SS-treated peptide mixture obtained above was added, and 3 μl of aqueous ammonia was added to adjust the pH to 9.5. After 20 hours, the reaction solution was analyzed by HPLC, and it was confirmed that 1.6 g of cyclized peptide A was generated with a purity of 73% (yield 80% relative to the deprotected / temporarily SS-treated peptide mixture).
[0459] Example 13: Temporary SS-Scheme Based on Thallium Trifluoroacetate Oxidation (Folding Concentration: 1 mg / ml)
[0460] Dissolve 50 mg of the tandem fully protected peptide A in 0.85 ml of chloroform and 0.05 ml of MeOH, and add 6 equivalents of thallium (III) trifluoroacetate and 36.8 mg. After the reaction, separate the liquid twice with a 20% NaCl aqueous solution. Concentrate the obtained organic layer with an evaporator and dry it. Add the solid to a mixed solution of 0.975 ml of TFA, 0.025 ml of water, and 24.4 mg of p-cresol for deprotection. Add 20 ml of IPE and filter the precipitate, and dry it to obtain 30.1 mg of a deprotected / temporarily SS-type peptide mixture. To a mixed solution of 1 ml of water, 1 ml of EtOH, 0.3 mg of cystine, and 0.3 mg of cysteine, 2.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained above was added, and 3 μl of aqueous ammonia was added to adjust the pH to 9.4. After 4 hours, the reaction solution was analyzed by HPLC, and it was confirmed that 1.3 g of cyclized peptide A was generated with a purity of 76% (91% yield relative to the tandem fully protected form of peptide A).
[0461] Preparation Example 5: Tandem fully protected peptide A''
[0462] Using Fmoc-Tyr(tBu)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Gly-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, and Fmoc-Glu(OtBu)-OH as raw materials and Alko-PEG resin (manufactured by Watanabe Chemical Industries, Ltd., Wang-PEG resin) as a solid phase protecting group, a tandem fully protected form of peptide A"' having the following sequence was synthesized according to a conventional method. It should be noted that the Fmoc group at the N-terminus of the following peptide was cleaved with a base according to a conventional method.
[0463] Tandem fully protected peptide A'':
[0464] H-Cys(Acm)-Cys(Acm)-Glu(OtBu)-Tyr(tBu)-Cys(Acm)-Cys(Acm)-Asn(Trt)-Pro-Ala-Cys(Acm)-Thr(tBu)-Gly-Cys(Acm)-Tyr(tBu)-Alko-PEG resin.
[0465] Example 14: Final deprotection / temporary SS-ylation route (folding concentration: 1 mg / ml)
[0466] The fully protected tandem peptide A'' was added to a mixed solution of 2.85 ml TFA, 75 μl water and 75 μl TIPS for deprotection. 30 ml IPE was added and the precipitate was filtered and dried to obtain 108 mg of a tandem peptide A'' having the following sequence.
[0467] Peptide A'' concatemer:
[0468] H-Cys(Acm)-Cys(Acm)-Glu-Tyr-Cys(Acm)-Cys(Acm)-Asn-Pro-Ala-Cys(Acm)-Thr-Gly-Cys(Acm)-Tyr-OH.
[0469] 10 mg of the concatemer of peptide A"' was dissolved in a mixed solution of 800 μl of acetic acid and 200 μl of water, and 10.4 mg of iodine (24 equivalents) was added. After reacting for 16 hours, the residual iodine was extracted 10 times with 1 ml of chloroform. The obtained aqueous layer was concentrated with an evaporator, IPE was added and the precipitate was filtered and dried to obtain a deprotected / temporarily SS-formed peptide mixture. 2.0 mg of the deprotected / temporarily SS-formed peptide mixture obtained above was added to a mixed solution of 1 ml of water, 1 ml of EtOH, 0.1 mg of cystine, and 0.1 mg of cysteine, and 3 μl of ammonia water was added to adjust the pH to 9.75. After 16 hours, when the reaction solution was analyzed by HPLC, it was confirmed that 1.4 g of cyclized peptide A was generated with a purity of 72% (yield 70% relative to the deprotected / temporarily SS-formed peptide mixture).
[0470] Preparation Example 6: Tandem fully protected peptide C
[0471] Using Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Ala-OH, Fmoc-Tyr(tBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-OH, Fmoc-Trp(Boc)-OH, Fmoc-Thr(tBu)-OH, and Fmoc-NH-SAL-PEG resin as solid phase protecting groups, a fully protected peptide C having the following sequence was synthesized according to a conventional method. It should be noted that the Fmoc group at the N-terminus of the following peptides was cleaved with a base according to a conventional method.
[0472] Tandem fully protected peptide C:
[0473] H-Arg(Pbf)-Gly-Asn(Trt)-Cys(Trt)-Ala-Tyr(tBu)-His(Trt)-Lys(Boc)-Gly-Gln(Trt)-Ile-Ile-Trp(Boc)-Cys(Trt)-Thr(tBu)-Tyr(tBu)-His(Trt)-NH-SAL-PEG resin.
[0474] Example 15: Temporary SS-S pathway based on iodine oxidation (folding concentration: 1 mg / ml)
[0475] 409 mg of the tandem fully protected form of peptide C was mixed and dissolved in 13.6 ml of chloroform and 2.4 ml of MeOH, and 1.5 equivalents of iodine and 9.5 mg were added. After the reaction, the solution was separated twice with an aqueous solution obtained by dissolving 44.0 mg of ascorbic acid in 16.0 ml of water, and then washed twice with a 20% NaCl aqueous solution. The obtained organic layer was concentrated and dried with an evaporator. The solid was added to a mixed solution of 8.39 ml of TFA, 0.21 ml of water, and 27.0 mg of p-cresol for deprotection. 20 ml of IPE was added and the precipitate was filtered and dried to obtain 30.1 mg of a deprotected / temporarily SS-ylated peptide mixture. To a mixed solution of 1.5 ml of water, 1.5 ml of EtOH, 0.3 mg of cystine, and 0.9 mg of cysteine, 3.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained above was added, and 3 μl of aqueous ammonia was added to adjust the pH to 9.0. After 3 hours, the reaction solution was analyzed by HPLC, confirming that cyclized peptide C was generated with a purity of 56%.
[0476] <Elution conditions>
[0477] Elution time: 3.78 minutes
[0478] Instrument used: Waters ACQUITY UPLC
[0479] Column: BEH Shield RP18 1.7μm 2.1×100mm
[0480] Temperature: 40℃
[0481] Flow rate: 0.30ml / min
[0482] Mobile phase: Liquid A, 0.05% TFA / H2O; Liquid B, 0.05% TFA / MeCN(20)THF(80)
[0483] Time program (Liquid A ratio)
[0484] 0.00-0.05 minutes 99%
[0485] 0.05-13.00 minutes 99-1%.
[0486] Cyclic peptide C:
[0487] H-Arg 1 -Gly 2 -Asn 3 -Cys 4 -Ala 5 -Tyr 6 -His 7 -Lys 8 -Gly 9 -Gln 10 -Ile 11 -Ile 12 -Trp 13 -Cys 14 -Thr 15 -Tyr 16 -His 17 -OH
[0488] (Here, in Cys 4 With Cys 14 SS bond is formed between them) (SEQ ID NO: 2)
[0489] m / z[M+H] + 2088.9.
[0490] Example 16: Temporary SS-S pathway based on iodine oxidation (folding concentration: 10 mg / ml)
[0491] To a mixed solution of 0.15 ml of water, 0.15 ml of EtOH, 0.3 mg of cystine, and 0.9 mg of cysteine, 3.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained in Example 15 was added, and 3 μl of aqueous ammonia was added to adjust the pH to 8.5. After 3 hours, the reaction solution was analyzed by HPLC, confirming that cyclized peptide C was generated with a purity of 55%.
[0492] Preparation Example 7: Tandem fully protected peptide D
[0493] Fmoc-Met-OH, Fmoc-Cys(Trt)-OH, Fmoc-Pro-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Tyr(tBu)-OH, and Fmoc-Leu-OH were used as raw materials, and di(4-docosanyloxyphenyl)methylamine (referred to as NHCH2(Phe(4-OC 22 H 45 ))2) As a pseudo solid phase protecting group, according to conventional methods (refer to International Publication No. 2012 / 029794; Angew Chem. Int. Ed. 2017.27, (56), 7803), a tandem fully protected peptide D having the following sequence was synthesized. It should be noted that in this specification, the concept of "fully protected peptide" includes the case where the N-terminal amino group can be protected, and therefore the peptide without protection at the N-terminus is also referred to as "tandem fully protected peptide". The Fmoc group at the N-terminus of the following peptide was cleaved with a base according to conventional methods.
[0494] Tandem fully protected peptide D:
[0495] H-Met-Cys(Trt)-Met-Pro-Cys(Trt)-Phe-Thr(tBu)-Thr(tBu)-Asp(OtBu)-His(Trt)-Gln(Trt)-Met-Ala-Arg(Pbf)-Lys(Boc)-Cys(Trt)-Asp(OtBu)-Asp(OtBu)-Cy s(Trt)-Cys(Trt)-Gly-Gly-Lys(Boc)-Gly-Arg(Pbf)-Gly-Lys(Boc)-Cys(Trt)-Tyr(tBu)-Gly-Pro-Gln(Trt)-Cys(Trt)-Leu-Cys(Trt)-Arg(Pbf)-NHCH2(Phe(4-OC 22 H 45 ))2.
[0496] Example 17: Temporary SS-S pathway based on iodine oxidation (folding concentration: 1 mg / ml)
[0497] Dissolve 200 mg of the tandem fully protected form of peptide D in 3.4 ml of chloroform and 0.6 ml of MeOH (methanol), and add 8 equivalents of iodine, 45.7 mg. After the reaction, separate the solution twice with an aqueous solution obtained by dissolving 39.6 mg of ascorbic acid in 3.4 ml of water, and wash twice with a 20% NaCl aqueous solution. Concentrate the obtained organic layer with an evaporator and dry it. Add the solid to a mixed solution of 3.9 ml of TFA, 0.1 ml of water, and 24.3 mg of p-cresol for deprotection. Add 20 ml of IPE and filter the precipitate, then dry it to obtain a deprotected / temporarily SS-type peptide mixture. To a mixed solution of 1 ml of water, 1 ml of EtOH, 0.3 mg of cystine, and 0.3 mg of cysteine, 2.0 mg of the deprotected / temporarily SS-ylated peptide mixture obtained above was added, and 3 μl of aqueous ammonia was added to adjust the pH to 9.1. After 1 hour, the reaction solution was analyzed by HPLC, confirming that cyclized peptide D was generated with a purity of 49.9%.
[0498] <Elution conditions>
[0499] Elution time: 3.26 minutes
[0500] Instrument used: Waters ACQUITY UPLC
[0501] Column: BEH Shield RP18 1.7μm 2.1×100mm
[0502] Temperature: 40℃
[0503] Flow rate: 0.30ml / min
[0504] Mobile phase: Liquid A, 0.05% TFA / H2O; Liquid B, 0.05% TFA / MeCN(20)THF(80)
[0505] Time program (Liquid A ratio)
[0506] 0.00-0.05 minutes 99%
[0507] 0.05-13.00 minutes 99-1%.
[0508] Cyclic peptide D:
[0509] H-Met 1 -Cys 2 -Met 3 -Pro 4 -Cys 5 -Phe 6 -Thr 7 -Thr 8 -Asp 9 -His10 -Gln 11 -Met 12 -Ala 13 -Arg 14 -Lys 15 -Cys 16 -Asp 17 -Asp 18 -Cys 19 -Cys 20 -Gly 21 -Gly 22 -Lys 23 -Gly 24 -Arg 25 -Gly 26 -Lys 27 -Cys 28 -Tyr 29 -Gly 30 -Pro 31 -Gln 32 -Cys 33 -Leu 34 -Cys 35 -Arg 36 -NH2
[0510] (Here, in Cys 2 With Cys 19 Between, Cys 5 With Cys 28 Between, Cys 16 With Cys 33 Between, Cys 20 With Cys 35 SS bond is formed between them) (SEQ ID NO: 3)
[0511] m / z[M+4H]4+999.6.
[0512] Possibility of industrial application
[0513] The present invention provides a method for producing a cyclized peptide having a cross-linked structure based on one or two or more intramolecular SS bonds, which is useful in the field of peptide synthesis.
[0514] This application is based on Japanese Patent Application No. 2018-216024 filed in Japan on November 16, 2018, the entire contents of which are incorporated herein by reference. Sequence Listing <110> Ajinomoto Co., Ltd. <120> Method for producing cyclized peptide having intramolecular SS bond <130> 092946 <150> JP2018-216024 <151> 2018-11-16 <160> 3 <170> PatentIn version 3.5 <210> 1 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Cyclic peptide A <220> <221> Disulfide (DISULFID) <222> (1)..(6) <220> <221> Disulfide <222> (2)..(10) <220> <221> Disulfide <222> (5)..(13) <400> 1 Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 <210> 2 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Cyclic peptide C <220> <221> Disulfide <222> (4)..(14) <400> 2 Arg Gly Asn Cys Ala Tyr His Lys Gly Gln Ile Ile Trp Cys Thr Tyr 1 5 10 15 His <210> 3 <211> 36 <212> PRT <213> Artificial sequence <220> <223> Cyclic peptide D <220> <221> Disulfide <222> (2)..(19) <220> <221> Disulfide <222> (5)..(28) <220> <221> Disulfide <222> (16)..(33) <220> <221> Disulfide <222> (20)..(35) <220> <221> MOD_RES <222> (36)..(36) <223> Amidation <400> 3 Met Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala Arg Lys Cys 1 5 10 15 Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro Gln 20 25 30 Cys Leu Cys Arg 35
Claims
1. A method for producing a cyclized peptide, the method comprising: (1-A) In a linear peptide having two or more SH groups as functional groups on the peptide, wherein all SH groups are protected, the N-terminal amino group may be protected, and the C-terminal carboxyl group and other functional groups on the peptide are all protected (hereinafter referred to as a "fully protected peptide"), a step of deprotecting the protecting groups of all functional groups of the peptide except the protected SH groups, (1-B) a step of protecting all SH groups in a linear peptide having two or more SH groups as functional groups on the peptide by forming temporary SS bonds, as well as (2) A peptide obtained by the above steps (1-A) and (1-B), wherein the peptide has two or more SH groups as functional groups on the peptide and all the SH groups are protected by forming temporary SS bonds, and all the protecting groups of other functional groups on the peptide are deprotected, is subjected to a folding step under redox conditions. The peptide is hereinafter referred to as an "S-protected peptide", and a cyclized peptide is obtained by re-forming SS bonds within the peptide molecule.
2. The method for producing a cyclized peptide according to claim 1, wherein In step (1-B), the protection of all SH groups by forming temporary SS bonds is achieved by forming temporary SS bonds of all SH groups within the peptide molecule and / or between peptide molecules, which is hereinafter referred to as "temporary SSization", or In step (1-B), the protection of all SH groups by forming a temporary SS bond is achieved by forming a temporary SS bond with an S-type protecting group.
3. The method for producing a cyclized peptide according to claim 2, wherein: In step (1-B), protection of all SH groups by forming temporary SS bonds is completed by temporary SS-reduction.
4. The method for producing a cyclized peptide according to claim 3, wherein Temporary SS-ization is performed by iodine treatment or thallium (III) trifluoroacetate treatment.
5. The method for producing a cyclized peptide according to claim 4, wherein Temporary SS treatment was performed by iodine treatment.
6. The method for producing a cyclized peptide according to claim 3, wherein In step (1-B), the fully protected peptide is subjected to temporary SS-reaction to obtain a mixture of peptides cross-linked or linked by temporary SS bonds, hereinafter referred to as "temporary SS-reaction peptide mixture", and then, In step (1-A), the protective groups of all functional groups of the temporarily SS-treated peptide mixture except the SH group protected by forming a temporary SS bond are deprotected to obtain an S-protected peptide.
7. The method for producing a cyclized peptide according to claim 6, wherein: The protecting group of the SH group in the fully protected peptide is a protecting group other than an S-type protecting group.
8. The method for producing a cyclized peptide according to claim 7, wherein The protecting group of the SH group in the fully protected peptide is a trityl group, namely a Trt group, an acetylaminomethyl group, namely an Acm group, a benzyl group, namely a Bzl group, a 4-methylbenzyl group, namely a 4-MeBzl group, or a 4-methoxybenzyl group, namely an MBzl group.
9. The method for producing a cyclized peptide according to any one of claims 6 to 8, wherein Temporary SS-ization is performed by iodine treatment or thallium (III) trifluoroacetate treatment.
10. The method for producing a cyclized peptide according to claim 9, wherein Temporary SS treatment was performed by iodine treatment.
11. The method for producing a cyclized peptide according to claim 3, wherein: In step (1-A), the protecting groups of all functional groups other than the SH group of the fully protected peptide are deprotected, and subsequently or simultaneously, In step (1-B), the deprotected peptide is subjected to temporary SS-reaction to obtain a temporary SS-reaction peptide mixture, thereby obtaining an S-protected peptide.
12. The method for producing a cyclized peptide according to claim 11, wherein The protecting groups for the SH group of the fully protected peptide are protecting groups other than S-type protecting groups.
13. The method for producing a cyclized peptide according to claim 12, wherein: The protecting group of the SH group in the fully protected peptide is an acetamidomethyl group, namely an Acm group, a tert-butyl group, namely a t-Bu group, a trityl group, namely a Trt group, a benzyl group, namely a Bzl group, a 4-methylbenzyl group, namely a 4-MeBzl group, or a 4-methoxybenzyl group, namely an MBzl group.
14. The method for producing a cyclized peptide according to any one of claims 11 to 13, wherein Temporary SS-ylation was performed by iodine treatment, DMSO / TFA treatment, or thallium (III) trifluoroacetate treatment.
15. The method for producing a cyclized peptide according to claim 14, wherein Temporary SS treatment was performed by iodine treatment.
16. The method for producing a cyclized peptide according to claim 3, wherein: a) 1) In step (1-A), all protective groups of the fully protected peptide except the SH group are deprotected, and then, 2) Remove the SH protecting group, and then 3) in step (1-B), subjecting the peptide to temporary SS to obtain a temporary SS-treated peptide mixture; or b) 1) removing the protecting groups of the SH groups of the fully protected peptide, and then, 2) In step (1-B), the peptide mixture is temporarily SS-treated to obtain a temporarily SS-treated peptide mixture, and then 3) In step (1-A), the protective groups of all functional groups of the temporarily SS-treated peptide mixture except the SH group protected by forming a temporary SS bond are deprotected to obtain an S-protected peptide.
17. The method for producing a cyclized peptide according to claim 16, wherein The protecting group for the SH group is a protecting group other than an S-type protecting group.
18. The method for producing a cyclized peptide according to claim 17, wherein: The protecting group of the SH group is a phenylacetylaminomethyl group, namely, a Phacm group, a 4-methoxybenzyl group, namely, an MBzl group, or a monomethoxytrityl group, namely, an MMTrt group.
19. The method for producing a cyclized peptide according to claim 18, wherein The protective group of the SH group is removed by the following treatment: Treatment with aqueous solution in the presence of penicillin amide hydrolase, PGA, Use DDQ treatment, or Use weak acid treatment.
20. The method for producing a cyclized peptide according to any one of claims 16 to 19, wherein Temporary SS-treatment is performed by iodine treatment, Npys-OMe treatment, or thallium (III) trifluoroacetate treatment.
21. The method for producing a cyclized peptide according to claim 20, wherein: Temporary SS treatment was performed by iodine treatment.
22. The method for producing a cyclized peptide according to claim 2, wherein: In step (1-B), the protection of all SH groups by forming a temporary SS bond is achieved by forming a temporary SS bond with an S-type protecting group.
23. The method for producing a cyclized peptide according to claim 22, wherein: In step (1-B), the protection of all SH groups by forming temporary SS bonds can be achieved by reprotecting the SH group with an S-type protecting group via a protecting group other than an S-type protecting group.
24. The method for producing a cyclized peptide according to claim 22 or 23, wherein: The S-type protecting group is 3-nitro-2-pyridinesulfinyl group, namely Npys group, tert-butylthiol group, namely S-tBu group, or ethylthiol group, namely S-Et group.
25. The method for producing a cyclized peptide according to any one of claims 22 to 24, wherein In step (1-B), the protecting group of the SH group of a linear peptide having two or more SH groups protected by protecting groups as functional groups on the peptide, wherein the N-terminal amino group may be protected and the C-terminal carboxyl group and all other functional groups on the peptide are protected, is re-protected with an S-type protecting group, or Pre-protected with an S-type protecting group, thereby obtaining a peptide in which all SH groups are protected by forming temporary SS bonds with the S-type protecting groups; In step (1-A), the protecting groups of all functional groups of the peptide except the SH group temporarily protected by the SS bond are deprotected to obtain an S-protected peptide.
26. The method for producing a cyclized peptide according to any one of claims 1 to 25, wherein The deprotection is carried out in the absence of a reducing agent.
27. The method for producing a cyclized peptide according to any one of claims 1 to 26, wherein The folding step under redox conditions in step (2) is performed in an aqueous solution having a pH of 6 or higher.
28. The method for producing a cyclized peptide according to any one of claims 1 to 27, wherein The folding step under redox conditions in step (2) is performed in the co-presence of an oxidizing agent and a reducing agent.
29. The method for producing a cyclized peptide according to any one of claims 1 to 28, wherein The number of SH groups in the S-protected peptide as functional groups on the peptide is two.
30. The method for producing a cyclized peptide according to any one of claims 1 to 28, wherein The number of SH groups in the S-protected peptide as functional groups on the peptide is 4 or more.
31. The method for producing a cyclized peptide according to any one of claims 1 to 30, wherein The number of SH groups in the S-protected peptide as functional groups on the peptide is an even number.
Citation Information
Patent Citations
Protecting group for synthesizing compound library
JP2000044493A
Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2
Support for crystallization separation and method of separating compound
WO2006104166A1
Carrier for separation, method for separation of compound, and method for synthesis of peptide using the carrier
WO2007034812A1
Reagent for organic synthesis and method of organic synthesis reaction with the reagent
WO2007122847A1
